Hubbry Logo
SerotoninSerotoninMain
Open search
Serotonin
Community hub
Serotonin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Serotonin
Serotonin
from Wikipedia

Serotonin
Skeletal formula of serotonin
Clinical data
Other names5-HT, 5-Hydroxytryptamine, Enteramine, Thrombocytin, 3-(β-Aminoethyl)-5-hydroxyl solution, Thrombotonin
Physiological data
Source tissuesraphe nuclei, enterochromaffin cells
Target tissuessystem-wide
Receptors5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7
AgonistsIndirectly: SSRIs, MAOIs
Precursor5-HTP
BiosynthesisAromatic L-amino acid decarboxylase
MetabolismMAO
Identifiers
  • 3-(2-Aminoethyl)-1H-indol-5-ol
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
KEGG
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.000.054 Edit this at Wikidata
Serotonin
Ball-and-stick model of the serotonin molecule
Ball-and-stick model of the serotonin molecule
Names
IUPAC name
5-Hydroxytryptamine
Preferred IUPAC name
3-(2-Aminoethyl)-1H-indol-5-ol
Other names
5-Hydroxytryptamine, 5-HT, Enteramine; Thrombocytin, 3-(β-Aminoethyl)-5-hydroxyindole, 3-(2-Aminoethyl)indol-5-ol, Thrombotonin
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.000.054 Edit this at Wikidata
KEGG
MeSH Serotonin
UNII
  • InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2 checkY
    Key: QZAYGJVTTNCVMB-UHFFFAOYSA-N checkY
  • InChI=1/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2
    Key: QZAYGJVTTNCVMB-UHFFFAOYAX
  • C1=CC2=C(C=C1O)C(=CN2)CCN
Properties
C10H12N2O
Molar mass 176.215 g/mol
Appearance White powder
Melting point 167.7 °C (333.9 °F; 440.8 K) 121–122 °C (ligroin)[3]
Boiling point 416 ± 30 °C (at 760 Torr)[1]
slightly soluble
Acidity (pKa) 10.16 in water at 23.5 °C[2]
2.98 D
Hazards
Lethal dose or concentration (LD, LC):
750 mg/kg (subcutaneous, rat),[4] 4500 mg/kg (intraperitoneal, rat),[5] 60 mg/kg (oral, rat)
Safety data sheet (SDS) External MSDS
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

Serotonin (/ˌsɛrəˈtnɪn, ˌsɪərə-/)[6][7][8], also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter with a wide range of functions in both the central nervous system (CNS) and also peripheral tissues. It is involved in mood, cognition, reward, learning, memory, and physiological processes such as vomiting and vasoconstriction.[9] In the CNS, serotonin regulates mood, appetite, and sleep.[10][11][unreliable medical source]

Most of the body's serotonin—about 90%—is synthesized in the gastrointestinal tract by enterochromaffin cells, where it regulates intestinal movements.[12][13][14] It is also produced in smaller amounts in the brainstem's raphe nuclei, the skin's Merkel cells, pulmonary neuroendocrine cells, and taste receptor cells of the tongue. Once secreted, serotonin is taken up by platelets in the blood, which release it during clotting to promote vasoconstriction and platelet aggregation.[15] Around 8% of the body's serotonin is stored in platelets, and 1–2% is found in the CNS.[16]

Serotonin acts as both a vasoconstrictor and vasodilator depending on concentration and context, influencing hemostasis and blood pressure regulation.[17] It plays a role in stimulating myenteric neurons and enhancing gastrointestinal motility through uptake and release cycles in platelets and surrounding tissue.[18] Biochemically, serotonin is an indoleamine synthesized from tryptophan and metabolized primarily in the liver to 5-hydroxyindoleacetic acid (5-HIAA).

Serotonin is targeted by several classes of antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs), which block reabsorption in the synapse to elevate its levels. It is found in nearly all bilateral animals, including insects, spiders and worms,[19] and also occurs in fungi and plants.[20] In plants and insect venom, it serves a defensive function by inducing pain.[21] Serotonin released by pathogenic amoebae may cause diarrhea in the human gut,[22] while its presence in seeds and fruits is thought to stimulate digestion and facilitate seed dispersal.[23][failed verification]

Molecular structure

[edit]

Biochemically, the indoleamine molecule derives from the amino acid tryptophan, via the (rate-limiting) hydroxylation of the 5 position on the ring (forming the intermediate 5-hydroxytryptophan), and then decarboxylation to produce serotonin.[24] Preferable conformations are defined via ethylamine chain, resulting in six different conformations.[25]

Crystal structure

[edit]

Serotonin crystallizes in P212121 chiral space group forming different hydrogen-bonding interactions between serotonin molecules via N-H...O and O-H...N intermolecular bonds.[26] Serotonin also forms several salts, including pharmaceutical formulation of serotonin adipate.[27]

Biological role

[edit]

Serotonin is involved in numerous physiological processes,[28] including sleep,[29] thermoregulation, learning and memory, pain, (social) behavior,[30] sexual activity, feeding, motor activity, neural development,[31] and biological rhythms.[32] In less complex animals, such as some invertebrates, serotonin regulates feeding and other processes.[33] In plants serotonin synthesis seems to be associated with stress signals.[20][34] Despite its longstanding prominence in pharmaceutical advertising, the claim that low serotonin levels cause depression is not supported by scientific evidence.[35][36][37]

Cellular effects

[edit]

Serotonin primarily acts through its receptors and its effects depend on which cells and tissues express these receptors.[32]

Metabolism involves first oxidation by monoamine oxidase to 5-hydroxyindoleacetaldehyde (5-HIAL).[38][39] The rate-limiting step is hydride transfer from serotonin to the flavin cofactor.[40] There follows oxidation by aldehyde dehydrogenase (ALDH) to 5-hydroxyindoleacetic acid (5-HIAA), the indole acetic-acid derivative. The latter is then excreted by the kidneys.

Receptors

[edit]

The serotonin receptors are located on the cell membrane of nerve cells and other cell types in animals, and mediate the effects of serotonin as the endogenous ligand and of a broad range of pharmaceutical and psychedelic drugs. There are currently 14 known serotonin receptors, including the serotonin 5-HT1 (1A, 1B, 1D, 1E, 1F), 5-HT2 (2A, 2B, 2C), 5-HT3, 5-HT4, 5-HT5 (5A, 5B), 5-HT6, and 5-HT7 receptors. Except for the serotonin 5-HT3 receptor, a ligand-gated ion channel, all other 5-HT receptors are G-protein-coupled receptors (also called seven-transmembrane, or heptahelical receptors) that activate an intracellular second messenger cascade.[41] The 5-HT5B receptor is present in rodents but not in humans.

In addition to the serotonin receptors, serotonin is an agonist of the trace amine-associated receptor 1 (TAAR1) in some species.[42][43] It is a weak TAAR1 partial agonist in rats, but is inactive at the TAAR1 in mice and humans.[42][43]

The cryo-EM structures of the serotonin 5-HT2A receptor with serotonin, as well as with various serotonergic psychedelics, have been solved and published by Bryan L. Roth and colleagues.[44][45]

Termination

[edit]

Serotonergic action is terminated primarily via uptake of 5-HT from the synapse. This is accomplished through the specific monoamine transporter for 5-HT, SERT, on the presynaptic neuron. Various agents can inhibit 5-HT reuptake, including cocaine, dextromethorphan (an antitussive), tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs). A 2006 study found that a significant portion of 5-HT's synaptic clearance is due to the selective activity of the plasma membrane monoamine transporter (PMAT) which actively transports the molecule across the membrane and back into the presynaptic cell.[46]

In contrast to the high affinity of SERT, the PMAT has been identified as a low-affinity transporter, with an apparent Km of 114 micromoles/l for serotonin, which is approximately 230 times higher than that of SERT. However, the PMAT, despite its relatively low serotonergic affinity, has a considerably higher transport "capacity" than SERT, "resulting in roughly comparable uptake efficiencies to SERT ... in heterologous expression systems."[46] The study also suggests that the administration of SSRIs such as fluoxetine and sertraline may be associated with an inhibitory effect on PMAT activity when used at higher than normal dosages (IC50 test values used in trials were 3–4 fold higher than typical prescriptive dosage).

Serotonylation

[edit]

Serotonin can also signal through a nonreceptor mechanism called serotonylation, in which serotonin modifies proteins.[47] This process underlies serotonin's effects upon platelet-forming cells (thrombocytes) in which it links to the modification of signaling enzymes called GTPases that then trigger the release of vesicle contents by exocytosis.[48] A similar process underlies the pancreatic release of insulin.[47]

The effects of serotonin upon vascular smooth muscle tone – the biological function after which serotonin was originally named – depend upon the serotonylation of proteins involved in the contractile apparatus of muscle cells.[49]

Binding profile of serotonin
Receptor Ki (nM)[50] Receptor function[Note 1]
5-HT1 receptor family signals via Gi/o inhibition of adenylyl cyclase.
5-HT1A 3.17 Memory[vague] (agonists ↓); learning[vague] (agonists ↓); anxiety (agonists ↓); depression (agonists ↓); positive, negative, and cognitive symptoms of schizophrenia (partial agonists ↓); analgesia (agonists ↑); aggression (agonists ↓); dopamine release in the prefrontal cortex (agonists ↑); serotonin release and synthesis (agonists ↓)
5-HT1B 4.32 Vasoconstriction (agonists ↑); aggression (agonists ↓); bone mass (↓). Serotonin autoreceptor.
5-HT1D 5.03 Vasoconstriction (agonists ↑)
5-HT1E 7.53
5-HT1F 10
5-HT2 receptor family signals via Gq activation of phospholipase C.
5-HT2A 11.55 Psychedelia (agonists ↑); depression (agonists & antagonists ↓); anxiety (antagonists ↓); positive and negative symptoms of schizophrenia (antagonists ↓); norepinephrine release from the locus coeruleus (antagonists ↑); glutamate release in the prefrontal cortex (agonists ↑); dopamine in the prefrontal cortex (agonists ↑);[51] urinary bladder contractions (agonists ↑)[52]
5-HT2B 8.71 Cardiovascular functioning (agonists increase risk of pulmonary hypertension), empathy (via von Economo neurons[53])
5-HT2C 5.02 Dopamine release into the mesocorticolimbic pathway (agonists ↓); acetylcholine release in the prefrontal cortex (agonists ↑); dopaminergic and noradrenergic activity in the frontal cortex (antagonists ↑);[54] appetite (agonists ↓); antipsychotic effects (agonists ↑); antidepressant effects (agonists & antagonists ↑)
Other 5-HT receptors
5-HT3 593 Emesis (agonists ↑); anxiolysis (antagonists ↑).
5-HT4 125.89 Movement of food across the GI tract (agonists ↑); memory & learning (agonists ↑); antidepressant effects (agonists ↑). Signalling via Gαs activation of adenylyl cyclase.
5-HT5A 251.2 Memory consolidation.[55] Signals via Gi/o inhibition of adenylyl cyclase.
5-HT6 98.41 Cognition (antagonists ↑); antidepressant effects (agonists & antagonists ↑); anxiogenic effects (antagonists ↑[56]). Gs signalling via activating adenylyl cyclase.
5-HT7 8.11 Cognition (antagonists ↑); antidepressant effects (antagonists ↑). Acts by Gs signalling via activating adenylyl cyclase.

Nervous system

[edit]
In this drawing of the brain, the serotonergic system is red and the mesolimbic dopamine pathway is blue. There is one collection of serotonergic neurons in the upper brainstem that sends axons upwards to the whole cerebrum, and one collection next to the cerebellum that sends axons downward to the spinal cord. Slightly forward the upper serotonergic neurons is the ventral tegmental area (VTA), which contains dopaminergic neurons. These neurons' axons then connect to the nucleus accumbens, hippocampus, and the frontal cortex. Over the VTA is another collection of dopaminergic cells, the substansia nigra, which send axons to the striatum.
Serotonin system, contrasted with the dopamine system

The neurons of the raphe nuclei are the principal source of 5-HT release in the brain.[57] There are nine raphe nuclei, designated B1–B9, which contain the majority of serotonin-containing neurons (some scientists chose to group the nuclei raphes lineares into one nucleus), all of which are located along the midline of the brainstem, and centered on the reticular formation.[58][59] Axons from the neurons of the raphe nuclei form a neurotransmitter system reaching almost every part of the central nervous system. Axons of neurons in the lower raphe nuclei terminate in the cerebellum and spinal cord, while the axons of the higher nuclei spread out in the entire brain.

It is the dorsal part of the raphe nucleus that contains neurons projecting to the central nervous system. Serotonin-releasing neurons in this area receive input from a large number of areas, notably from prefrontal cortex, lateral habenula, preoptic area, substantia nigra and amygdala.[60] These neurons are thought to communicate the expectation of rewards in the near future, a quantity called state value in reinforcement learning.[61]

Ultrastructure and function

[edit]

The serotonin nuclei may also be divided into two main groups, the rostral and caudal containing three and four nuclei respectively. The rostral group consists of the caudal linear nuclei (B8), the dorsal raphe nuclei (B6 and B7) and the median raphe nuclei (B5, B8 and B9), that project into multiple cortical and subcortical structures. The caudal group consists of the nucleus raphe magnus (B3), raphe obscurus nucleus (B2), raphe pallidus nucleus (B1), and lateral medullary reticular formation, that project into the brainstem.[62]

The serotonergic pathway is involved in sensorimotor function, with pathways projecting both into cortical (Dorsal and Median Raphe Nuclei), subcortical, and spinal areas involved in motor activity. Pharmacological manipulation suggests that serotonergic activity increases with motor activity while firing rates of serotonergic neurons increase with intense visual stimuli. Animal models suggest that kainate signaling negatively regulates serotonin actions in the retina, with possible implications for the control of the visual system.[63] The descending projections form a pathway that inhibits pain called the "descending inhibitory pathway" that may be relevant to a disorder such as fibromyalgia, migraine, and other pain disorders, and the efficacy of antidepressants in them.[64]

Serotonergic projections from the caudal nuclei are involved in regulating mood and emotion, and hypo-[65] or hyper-serotonergic[66] states may be involved in depression and sickness behavior.

Microanatomy

[edit]

Serotonin is released into the synapse, or space between neurons, and diffuses over a relatively wide gap (>20 nm) to activate 5-HT receptors located on the dendrites, cell bodies, and presynaptic terminals of adjacent neurons.

When humans smell food, dopamine is released to increase the appetite. But, unlike in worms, serotonin does not increase anticipatory behaviour in humans; instead, the serotonin released while consuming activates 5-HT2C receptors on dopamine-producing cells. This halts their dopamine release, and thereby serotonin decreases appetite. Drugs that block 5-HT2C receptors make the body unable to recognize when it is no longer hungry or otherwise in need of nutrients, and are associated with weight gain,[67] especially in people with a low number of receptors.[68] The expression of 5-HT2C receptors in the hippocampus follows a diurnal rhythm,[69] just as the serotonin release in the ventromedial nucleus, which is characterised by a peak at morning when the motivation to eat is strongest.[70]

In macaques, alpha males have twice the level of serotonin in the brain as subordinate males and females (measured by the concentration of 5-HIAA in the cerebrospinal fluid (CSF)). Dominance status and CSF serotonin levels appear to be positively correlated. When dominant males were removed from such groups, subordinate males begin competing for dominance. Once new dominance hierarchies were established, serotonin levels of the new dominant individuals also increased to double those in subordinate males and females. The reason why serotonin levels are only high in dominant males, but not dominant females has not yet been established.[71]

In humans, levels of 5-HT1A receptor inhibition in the brain show negative correlation with aggression,[72] and a mutation in the gene that codes for the 5-HT2A receptor may double the risk of suicide for those with that genotype.[73] Serotonin in the brain is not usually degraded after use, but is collected by serotonergic neurons by serotonin transporters on their cell surfaces. Studies have revealed nearly 10% of total variance in anxiety-related personality depends on variations in the description of where, when and how many serotonin transporters the neurons should deploy.[74]

Outside the nervous system

[edit]

Digestive tract (emetic)

[edit]

Serotonin regulates gastrointestinal (GI) function. The gut is surrounded by enterochromaffin cells, which release serotonin in response to food in the lumen. This makes the gut contract around the food. Platelets in the veins draining the gut collect excess serotonin. There are often serotonin abnormalities in gastrointestinal disorders such as constipation and irritable bowel syndrome.[75]

If irritants are present in the food, the enterochromaffin cells release more serotonin to make the gut move faster, i.e., to cause diarrhea, so the gut is emptied of the noxious substance. If serotonin is released in the blood faster than the platelets can absorb it, the level of free serotonin in the blood is increased. This activates 5-HT3 receptors in the chemoreceptor trigger zone that stimulate vomiting.[76] Thus, drugs and toxins stimulate serotonin release from enterochromaffin cells in the gut wall which can induce emesis. The enterochromaffin cells not only react to bad food but are also very sensitive to irradiation and cancer chemotherapy. Drugs that block 5HT3 are very effective in controlling the nausea and vomiting produced by cancer treatment, and are considered the gold standard for this purpose.[77]

Lungs

[edit]

The lung,[78] including that of reptiles,[79] contains specialized epithelial cells that occur as solitary cells or as clusters called neuroepithelial bodies or bronchial Kulchitsky cells or alternatively K cells.[80] These are enterochromaffin cells that like those in the gut release serotonin.[80] Their function is probably vasoconstriction during hypoxia.[78]

Skin

[edit]

Serotonin is also produced by Merkel cells which are part of the somatosensory system.[81]

Bone metabolism

[edit]

In mice and humans, alterations in serotonin levels and signalling have been shown to regulate bone mass.[82][83][84][85] Mice that lack brain serotonin have osteopenia, while mice that lack gut serotonin have high bone density. In humans, increased blood serotonin levels have been shown to be a significant negative predictor of low bone density. Serotonin can also be synthesized, albeit at very low levels, in the bone cells. It mediates its actions on bone cells using three different receptors. Through 5-HT1B receptors, it negatively regulates bone mass, while it does so positively through 5-HT2B receptors and 5-HT2C receptors. There is very delicate balance between physiological role of gut serotonin and its pathology. Increase in the extracellular content of serotonin results in a complex relay of signals in the osteoblasts culminating in FoxO1/ Creb and ATF4 dependent transcriptional events.[86] Following the 2008 findings that gut serotonin regulates bone mass, the mechanistic investigations into what regulates serotonin synthesis from the gut in the regulation of bone mass have started. Piezo1 has been shown to sense RNA in the gut and relay this information through serotonin synthesis to the bone by acting as a sensor of single-stranded RNA (ssRNA) governing 5-HT production. Intestinal epithelium-specific deletion of mouse Piezo1 profoundly disturbed gut peristalsis, impeded experimental colitis, and suppressed serum 5-HT levels. Because of systemic 5-HT deficiency, conditional knockout of Piezo1 increased bone formation. Notably, fecal ssRNA was identified as a natural Piezo1 ligand, and ssRNA-stimulated 5-HT synthesis from the gut was evoked in a MyD88/TRIF-independent manner. Colonic infusion of RNase A suppressed gut motility and increased bone mass. These findings suggest gut ssRNA as a master determinant of systemic 5-HT levels, indicating the ssRNA-Piezo1 axis as a potential prophylactic target for treatment of bone and gut disorders. Studies in 2008, 2010 and 2019 have opened the potential for serotonin research to treat bone mass disorders.[87][88]

Organ development

[edit]

Since serotonin signals resource availability it is not surprising that it affects organ development. Many human and animal studies have shown that nutrition in early life can influence, in adulthood, such things as body fatness, blood lipids, blood pressure, atherosclerosis, behavior, learning, and longevity.[89][90][91] Rodent experiment shows that neonatal exposure to SSRIs makes persistent changes in the serotonergic transmission of the brain resulting in behavioral changes,[92][93] which are reversed by treatment with antidepressants.[94] By treating normal and knockout mice lacking the serotonin transporter with fluoxetine scientists showed that normal emotional reactions in adulthood, like a short latency to escape foot shocks and inclination to explore new environments were dependent on active serotonin transporters during the neonatal period.[95][96]

Human serotonin can also act as a growth factor directly. Liver damage increases cellular expression of 5-HT2A and 5-HT2B receptors, mediating liver compensatory regrowth (see Liver § Regeneration and transplantation)[97] Serotonin present in the blood then stimulates cellular growth to repair liver damage.[98]

5-HT2B receptors also activate osteocytes, which build up bone[99] However, serotonin also inhibits osteoblasts, through 5-HT1B receptors.[100]

Cardiovascular growth factor

[edit]

Serotonin, in addition, evokes endothelial nitric oxide synthase activation and stimulates, through a 5-HT1B receptor-mediated mechanism, the phosphorylation of p44/p42 mitogen-activated protein kinase activation in bovine aortic endothelial cell cultures.[clarification needed][101] In blood, serotonin is collected from plasma by platelets, which store it. It is thus active wherever platelets bind in damaged tissue, as a vasoconstrictor to stop bleeding, and also as a fibrocyte mitotic (growth factor), to aid healing.[102]

Adipose tissue

[edit]

Serotonin also regulates white and brown adipose tissue function, and adipocytes are capable of producing 5-HT separately from the gut. Serotonin increases lipogenesis through HTR2A in white adipose tissue, and suppressed thermogenesis in brown adipose tissue via Htr3.[103]

Pharmacology

[edit]

Several classes of drugs target the serotonin system, including some antidepressants, anxiolytics, antipsychotics, analgesics, antimigraine drugs, oxytocics, antiemetics, appetite suppressants, and anticonvulsants, as well as psychedelics and entactogens.

Mechanism of action

[edit]

At rest, serotonin is stored within the vesicles of presynaptic neurons. When stimulated by nerve impulses, serotonin is released as a neurotransmitter into the synapse, reversibly binding to the postsynaptic receptor to induce a nerve impulse on the postsynaptic neuron. Serotonin can also bind to auto-receptors on the presynaptic neuron to regulate the synthesis and release of serotonin. Normally serotonin is taken back into the presynaptic neuron to stop its action, then reused or broken down by monoamine oxidase.[104]

Antidepressants

[edit]

Drugs that alter serotonin levels are used in treating depression, generalized anxiety disorder, and social phobia. Monoamine oxidase inhibitors (MAOIs) prevent the breakdown of monoamine neurotransmitters (including serotonin), and therefore increase concentrations of the neurotransmitter in the brain. MAOI therapy is associated with many adverse drug reactions, and patients are at risk of hypertensive emergency triggered by foods with high tyramine content, and certain drugs. Some drugs inhibit the re-uptake of serotonin, making it stay in the synaptic cleft longer. The tricyclic antidepressants (TCAs) inhibit the reuptake of both serotonin and norepinephrine. The newer selective serotonin reuptake inhibitors (SSRIs) have fewer side-effects and fewer interactions with other drugs.[105]

Certain SSRI medications have been shown to lower serotonin levels below the baseline after chronic use, despite initial increases.[106] The 5-HTTLPR gene codes for the number of serotonin transporters in the brain, with more serotonin transporters causing decreased duration and magnitude of serotonergic signaling.[107] The 5-HTTLPR polymorphism (l/l) causing more serotonin transporters to be formed is also found to be more resilient against depression and anxiety.[108][109]

Besides their use in treating depression and anxiety, certain serotonergic antidepressants are also approved and used to treat fibromyalgia, neuropathic pain, and chronic fatigue syndrome.[110][111]

Anxiolytics

[edit]

Azapirone anxiolytics like buspirone and tandospirone act as serotonin 5-HT1A receptor agonists.[112][113]

Antipsychotics

[edit]

Many antipsychotics bind to and modulate serotonin receptors, including the serotonin 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 receptors, among others.[114][115] Activation of serotonin 5-HT1A receptors and blockade of serotonin 5-HT2A receptors may contribute to the therapeutic antipsychotic effects of these agents, whereas antagonism of serotonin 5-HT2C receptors has been especially implicated in side effects of antipsychotics.[114][115]

Antimigraine agents

[edit]

Antimigraine agents such as the triptans like sumatriptan act as agonists of the serotonin 5-HT1B, 5-HT1D, and/or 5-HT1F receptors.[116][117] Earlier antimigraine agents were the ergoline derivatives and ergot-related drugs such as ergotamine, dihydroergotamine, and methysergide, which act as non-selective serotonin receptor agonists.[117][118][119]

Oxytocics

[edit]

Certain lysergamides like ergometrine and methylergometrine are used clinically as oxytocic agents.[120][121] The oxytocic effects of these drugs are thought to most likely be mediated by agonism of serotonin 5-HT2 receptors in uterine smooth muscle tissue.[120][121]

Antiemetics

[edit]

Some serotonin 5-HT3 receptor antagonists, such as ondansetron, granisetron, and tropisetron, are important antiemetic agents.[122][123] They are particularly important in treating the nausea and vomiting that occur during anticancer chemotherapy using cytotoxic drugs.[123] Another application is in the treatment of postoperative nausea and vomiting.[122]

Appetite suppressants

[edit]

Some serotonin releasing agents, serotonin reuptake inhibitors, and/or serotonin 5-HT2C receptor agonists, such as fenfluramine, dexfenfluramine, chlorphentermine, sibutramine, and lorcaserin, have been approved and used as appetite suppressants for purposes of weight loss in the treatment of overweightness or obesity.[124][125][126][127][128] Several of the preceding agents have been withdrawn from the market due to toxicity, such as cardiac fibrosis or pulmonary hypertension.[128]

Anticonvulsants

[edit]

Although it was previously withdrawn from the market as an appetite suppressant, fenfluramine was reintroduced as an anticonvulsant for treatment of seizures in certain rare forms of epilepsy like Dravet syndrome and Lennox–Gastaut syndrome.[129] Selective serotonin 5-HT2C receptor agonists, like lorcaserin, bexicaserin, and BMB-101, are also being developed for this use.[129][130][131][132]

Psychedelics

[edit]

Serotonergic psychedelics, including drugs like psilocybin (found in psilocybin mushrooms), dimethyltryptamine (DMT) (found in ayahuasca), lysergic acid diethylamide (LSD), mescaline (found in peyote cactus), and 5-MeO-DMT (found in Anadenanthera trees and the Bufo alvarius toad), are non-selective agonists of the serotonin receptors and mediate their hallucinogenic effects specifically by activation of the serotonin 5-HT2A receptor.[133][134][135] This is evidenced by the fact that serotonin 5-HT2A receptor antagonists and so-called "trip killers" like ketanserin block the hallucinogenic effects of serotonergic psychedelics in humans, among many other findings.[133][134][136] Some serotonergic psychedelics, like psilocin, DMT, and 5-MeO-DMT, are substituted tryptamines and are very similar in chemical structure to serotonin.[135]

Serotonin itself, despite acting as a serotonin 5-HT2A receptor agonist, is thought to be non-hallucinogenic.[137] The hallucinogenic effects of serotonergic psychedelics appear to be mediated by activation of serotonin 5-HT2A receptors expressed in a population of cortical neurons in the medial prefrontal cortex (mPFC).[138][137] These serotonin 5-HT2A receptors, unlike most serotonin and related receptors, are expressed intracellularly.[138][137] In addition, the neurons containing them lack expression of the serotonin transporter (SERT), which normally transports serotonin from the extracellular space to the intracellular space within neurons.[138][137] Serotonin itself is too hydrophilic to enter serotonergic neurons without the SERT, and hence these serotonin 5-HT2A receptors are inaccessible to serotonin.[138][137] Conversely, serotonergic psychedelics are more lipophilic than serotonin and readily enter these neurons.[138][137] In addition to explaining why serotonin does not show psychedelic effects, these findings may explain why drugs that increase serotonin levels, like selective serotonin reuptake inhibitors (SSRIs) and various other types of serotonergic agents, do not produce psychedelic effects.[138][137] Artificial expression of the SERT in these medial prefrontal cortex neurons resulted in the serotonin releasing agent para-chloroamphetamine (PCA), which does not normally show psychedelic-like effects, being able to produce psychedelic-like effects in animals.[137]

Although serotonin itself is non-hallucinogenic, administration of very high doses of a serotonin precursor, like tryptophan or 5-hydroxytryptophan (5-HTP), or intracerebroventricular injection of high doses of serotonin directly into the brain, can produce psychedelic-like effects in animals.[139][140][141] These psychedelic-like effects can be abolished by indolethylamine N-methyltransferase (INMT) inhibitors, which block conversion of serotonin and other endogenous tryptamines into N-methylated tryptamines, including N-methylserotonin (NMS; norbufotenin), bufotenin (5-hydroxy-N,N-dimethyltryptamine; 5-HO-DMT), N-methyltryptamine (NMT), and N,N-dimethyltryptamine (DMT).[140][142][141] These N-methyltryptamines are much more lipophilic than serotonin and, in contrast, are able to diffuse into serotonergic neurons and activate intracellular serotonin 5-HT2A receptors.[140][141][138][137] Another possible metabolite of serotonin with psychedelic-like effects in animals is 5-methoxytryptamine (5-MT).[143][144][145]

DMT is a naturally occurring endogenous compound in the body.[146][147][148] In relation to the fact that serotonin itself is unable to activate intracellular serotonin 5-HT2A receptors, it is possible that DMT might be the endogenous ligand of these receptors rather than serotonin.[138][137]

Entactogens

[edit]

The entactogen MDMA is a serotonin releasing agent and, while it also possesses other actions such as concomitant release of norepinephrine and dopamine and weak direct agonism of the serotonin 5-HT2 receptors, its serotonin release plays a key role in its unique entactogenic effects.[149] Entactogens like MDMA should be distinguished from other drugs such as stimulants like amphetamine and psychedelics like LSD, although MDMA itself also has some characteristics of both of these types of agents.[149][150] Coadministration of selective serotonin reuptake inhibitors (SSRIs), which block the serotonin transporter (SERT) and prevent MDMA from inducing serotonin release, markedly reduce the subjective effects of MDMA, demonstrating the key role of serotonin in the effects of the drug.[151] Serotonin releasing agents like MDMA achieve much greater increases in serotonin levels than SSRIs and have far more robust of subjective effects.[152][153][154][155] Besides MDMA, many other entactogens also exist and are known.[156][157][150]

Serotonin syndrome

[edit]

Extremely high levels of serotonin or activation of certain serotonin receptors can cause a condition known as serotonin syndrome, with toxic and potentially fatal effects. In practice, such toxic levels are essentially impossible to reach through an overdose of a single antidepressant drug, but require a combination of serotonergic agents, such as an SSRI with a MAOI, which may occur in therapeutic doses.[158][159] However, serotonin syndrome can occur with overdose of certain serotonin receptor agonists, like the NBOMe series of serotonergic psychedelics.[160][161][162]

The intensity of the symptoms of serotonin syndrome vary over a wide spectrum, and the milder forms are seen even at nontoxic levels.[163] It is estimated that 14% of patients experiencing serotonin syndrome overdose on SSRIs; while the fatality rate is between 2% and 12%.[158][164][165]

Cardiac fibrosis and other fibroses

[edit]

Some serotonergic agonist drugs cause fibrosis anywhere in the body, particularly the syndrome of retroperitoneal fibrosis, as well as cardiac valve fibrosis.[166]

In the past, three groups of serotonergic drugs have been epidemiologically linked with these syndromes. These are the serotonergic vasoconstrictive antimigraine drugs (ergotamine and methysergide),[166] the serotonergic appetite suppressant drugs (fenfluramine, chlorphentermine, and aminorex), and certain anti-Parkinsonian dopaminergic agonists, which also stimulate serotonergic 5-HT2B receptors. These include pergolide and cabergoline, but not the more dopamine-specific lisuride.[167]

As with fenfluramine, some of these drugs have been withdrawn from the market after groups taking them showed a statistical increase of one or more of the side effects described. An example is pergolide. The drug was declining in use since it was reported in 2003 to be associated with cardiac fibrosis.[168]

Two independent studies published in The New England Journal of Medicine in January 2007 implicated pergolide, along with cabergoline, in causing valvular heart disease.[169][170] As a result of this, the FDA removed pergolide from the United States market in March 2007.[171] (Since cabergoline is not approved in the United States for Parkinson's Disease, but for hyperprolactinemia, the drug remains on the market. Treatment for hyperprolactinemia requires lower doses than that for Parkinson's Disease, diminishing the risk of valvular heart disease).[172]

Comparative biology and evolution

[edit]

Unicellular organisms

[edit]

Serotonin is used by a variety of single-cell organisms for various purposes. SSRIs have been found to be toxic to algae.[173] The gastrointestinal parasite Entamoeba histolytica secretes serotonin, causing a sustained secretory diarrhea in some people.[22][174] Patients infected with E. histolytica have been found to have highly elevated serum serotonin levels, which returned to normal following resolution of the infection.[175] E. histolytica also responds to the presence of serotonin by becoming more virulent.[176] This means serotonin secretion not only serves to increase the spread of entamoebas by giving the host diarrhea but also serves to coordinate their behaviour according to their population density, a phenomenon known as quorum sensing. Outside the gut of a host, there is nothing that the entamoebas provoke to release serotonin, hence the serotonin concentration is very low. Low serotonin signals to the entamoebas they are outside a host and they become less virulent to conserve energy. When they enter a new host, they multiply in the gut, and become more virulent as the enterochromaffine cells get provoked by them and the serotonin concentration increases.

Edible plants and mushrooms

[edit]

In drying seeds, serotonin production is a way to get rid of the buildup of poisonous ammonia. The ammonia is collected and placed in the indole part of L-tryptophan, which is then decarboxylated by tryptophan decarboxylase to give tryptamine, which is then hydroxylated by a cytochrome P450 monooxygenase, yielding serotonin.[177]

However, since serotonin is a major gastrointestinal tract modulator, it may be produced in the fruits of plants as a way of speeding the passage of seeds through the digestive tract, in the same way as many well-known seed and fruit associated laxatives. Serotonin is found in mushrooms, fruits, and vegetables. The highest values of 25–400 mg/kg have been found in nuts of the walnut (Juglans) and hickory (Carya) genera. Serotonin concentrations of 3–30 mg/kg have been found in plantains, pineapples, banana, kiwifruit, plums, and tomatoes. Moderate levels from 0.1–3 mg/kg have been found in a wide range of tested vegetables.[23][20]

Serotonin is one compound of the poison contained in stinging nettles (Urtica dioica), where it causes pain on injection in the same manner as its presence in insect venoms.[21] It is also naturally found in Paramuricea clavata, or the Red Sea Fan.[178]

Serotonin and tryptophan have been found in chocolate with varying cocoa contents. The highest serotonin content (2.93 μg/g) was found in chocolate with 85% cocoa, and the highest tryptophan content (13.27–13.34 μg/g) was found in 70–85% cocoa. The intermediate in the synthesis from tryptophan to serotonin, 5-hydroxytryptophan, was not found.[179]

Root development in Arabidopsis thaliana is stimulated and modulated by serotonin – in various ways at various concentrations.[180]

Serotonin serves as a plant defense chemical against fungi. When infected with Fusarium crown rot (Fusarium pseudograminearum), wheat (Triticum aestivum) greatly increases its production of tryptophan to synthesize new serotonin.[181] The function of this is poorly understood[181] but wheat also produces serotonin when infected by Stagonospora nodorum – in that case to retard spore production.[182] The model cereal Brachypodium distachyon – used as a research substitute for wheat and other production cereals – also produces serotonin, coumaroyl-serotonin, and feruloyl-serotonin in response to F. graminearum. This produces a slight antimicrobial effect. B. distachyon produces more serotonin (and conjugates) in response to deoxynivalenol (DON)-producing F. graminearum than non-DON-producing.[183] Solanum lycopersicum produces many AA conjugates – including several of serotonin – in its leaves, stems, and roots in response to Ralstonia solanacearum infection.[184]

Serotonin occurs in several hallucinogenic mushrooms of the genus Panaeolus.[185]

Invertebrates

[edit]

Serotonin functions as a neurotransmitter in the nervous systems of most animals.

Nematodes

[edit]

For example, in the roundworm Caenorhabditis elegans, which feeds on bacteria, serotonin is released as a signal in response to positive events, such as finding a new source of food or in male animals finding a female with which to mate.[186] When a well-fed worm feels bacteria on its cuticle, dopamine is released, which slows it down; if it is starved, serotonin also is released, which slows the animal down further. This mechanism increases the amount of time animals spend in the presence of food.[187] The released serotonin activates the muscles used for feeding, while octopamine suppresses them.[188][189] Serotonin diffuses to serotonin-sensitive neurons, which control the animal's perception of nutrient availability.

Decapods

[edit]

If lobsters are injected with serotonin, they behave like dominant individuals whereas octopamine causes subordinate behavior.[30] A crayfish that is frightened may flip its tail to flee, and the effect of serotonin on this behavior depends largely on the animal's social status. Serotonin inhibits the fleeing reaction in subordinates, but enhances it in socially dominant or isolated individuals. The reason for this is social experience alters the proportion between serotonin receptors (5-HT receptors) that have opposing effects on the fight-or-flight response.[clarification needed] The effect of 5-HT1 receptors predominates in subordinate animals, while 5-HT2 receptors predominates in dominants.[190]

In venoms

[edit]

Serotonin is a common component of invertebrate venoms, salivary glands, nervous tissues, and various other tissues, across molluscs, insects, crustaceans, scorpions, various kinds of worms, and jellyfish.[21] Adult Rhodnius prolixushematophagous on vertebrates – secrete lipocalins into the wound during feeding. In 2003 these lipocalins were demonstrated to sequester serotonin to prevent vasoconstriction (and possibly coagulation) in the host.[191]

Insects

[edit]

Serotonin is evolutionarily conserved and appears across the animal kingdom. It is seen in insect processes in roles similar to in the human central nervous system, such as memory, appetite, sleep, and behavior.[192][19] Some circuits in mushroom bodies are serotonergic.[193] (See specific Drosophila example below, §Dipterans.)

Acrididae
[edit]

Locust swarming is initiated but not maintained by serotonin,[194] with release being triggered by tactile contact between individuals.[195] This transforms social preference from aversion to a gregarious state that enables coherent groups.[196][195][194] Learning in flies and honeybees is affected by the presence of serotonin.[197][198]

Role in insecticides
[edit]

Insect 5-HT receptors have similar sequences to the vertebrate versions, but pharmacological differences have been seen. Invertebrate drug response has been far less characterized than mammalian pharmacology and the potential for species selective insecticides has been discussed.[199]

Hymenopterans
[edit]

Wasps and hornets have serotonin in their venom,[200] which causes pain and inflammation[201][21] as do scorpions.[202][21] Pheidole dentata takes on more and more tasks in the colony as it gets older, which requires it to respond to more and more olfactory cues in the course of performing them. This olfactory response broadening was demonstrated to go along with increased serotonin and dopamine, but not octopamine in 2006.[203]

Dipterans
[edit]

If flies are fed serotonin, they are more aggressive; flies depleted of serotonin still exhibit aggression, but they do so much less frequently.[204] In their crops it plays a vital role in digestive motility produced by contraction. Serotonin that acts on the crop is exogenous to the crop itself and 2012 research suggested that it probably originated in the serotonin neural plexus in the thoracic-abdominal synganglion.[205] In 2011 a Drosophila serotonergic mushroom body was found to work in concert with Amnesiac to form memories.[193] In 2007 serotonin was found to promote aggression in Diptera, which was counteracted by neuropeptide F – a surprising find given that they both promote courtship, which is usually similar to aggression in most respects.[193]

Vertebrates

[edit]

Serotonin, also referred to as 5-hydroxytryptamine (5-HT), is a neurotransmitter most known for its involvement in mood disorders in humans. It is also a widely present neuromodulator among vertebrates and invertebrates.[206] Serotonin has been found having associations with many physiological systems such as cardiovascular, thermoregulation, and behavioral functions, including: circadian rhythm, appetite, aggressive and sexual behavior, sensorimotor reactivity and learning, and pain sensitivity.[207] Serotonin's function in neurological systems along with specific behaviors among vertebrates found to be strongly associated with serotonin will be further discussed. Two relevant case studies are also mentioned regarding serotonin development involving teleost fish and mice.

In mammals, 5-HT is highly concentrated in the substantia nigra, ventral tegmental area and raphe nuclei. Lesser concentrated areas include other brain regions and the spinal cord.[206] 5-HT neurons are also shown to be highly branched, indicating that they are structurally prominent for influencing multiple areas of the CNS at the same time, although this trend is exclusive solely to mammals.[207]

5-HT system in vertebrates

[edit]

Vertebrates are multicellular organisms in the phylum Chordata that possess a backbone and a nervous system. This includes mammals, fish, reptiles, birds, etc. In humans, the nervous system is composed of the central and peripheral nervous system, with little known about the specific mechanisms of neurotransmitters in most other vertebrates. However, it is known that while serotonin is involved in stress and behavioral responses, it is also important in cognitive functions.[206] Brain organization in most vertebrates includes 5-HT cells in the hindbrain.[206] In addition to this, 5-HT is often found in other sections of the brain in non-placental vertebrates, including the basal forebrain and pretectum.[208] Since location of serotonin receptors contribute to behavioral responses, this suggests serotonin is part of specific pathways in non-placental vertebrates that are not present in amniotic organisms.[209] Teleost fish and mice are organisms most often used to study the connection between serotonin and vertebrate behavior. Both organisms show similarities in the effect of serotonin on behavior, but differ in the mechanism in which the responses occur.

Dogs / canine species
[edit]

There are few studies of serotonin in dogs. One study reported serotonin values were higher at dawn than at dusk.[210] In another study, serum 5-HT levels did not seem to be associated with dogs' behavioural response to a stressful situation.[211] Urinary serotonin/creatinine ratio in bitches tended to be higher 4 weeks after surgery. In addition, serotonin was positively correlated with both cortisol and progesterone but not with testosterone after ovariohysterectomy.[212]

Teleost fish
[edit]

Like non-placental vertebrates, teleost fish also possess 5-HT cells in other sections of the brain, including the basal forebrain.[208] Danio rerio (zebra fish) are a species of teleost fish often used for studying serotonin within the brain. Despite much being unknown about serotonergic systems in vertebrates, the importance in moderating stress and social interaction is known.[213] It is hypothesized that AVT and CRF cooperate with serotonin in the hypothalamic-pituitary-interrenal axis.[208] These neuropeptides influence the plasticity of the teleost, affecting its ability to change and respond to its environment. Subordinate fish in social settings show a drastic increase in 5-HT concentrations.[213] High levels of 5-HT long term influence the inhibition of aggression in subordinate fish.[213]

Mice
[edit]

Researchers at the Department of Pharmacology and Medical Chemistry used serotonergic drugs on male mice to study the effects of selected drugs on their behavior.[214] Mice in isolation exhibit increased levels of agonistic behavior towards one another. Results found that serotonergic drugs reduce aggression in isolated mice while simultaneously increasing social interaction.[214] Each of the treatments use a different mechanism for targeting aggression, but ultimately all have the same outcome. While the study shows that serotonergic drugs successfully target serotonin receptors, it does not show specifics of the mechanisms that affect behavior, as all types of drugs tended to reduce aggression in isolated male mice.[214] Aggressive mice kept out of isolation may respond differently to changes in serotonin reuptake.

Behavior

[edit]

Like in humans, serotonin is involved in regulating behavior in most other vertebrates. This includes not only response and social behaviors, but also influencing mood. Defects in serotonin pathways can lead to intense variations in mood, as well as symptoms of mood disorders, which can be present in more than just humans.

Social interaction
[edit]

One of the most researched aspects of social interaction in which serotonin is involved is aggression. Aggression is regulated by the 5-HT system, as serotonin levels can both induce or inhibit aggressive behaviors, as seen in mice (see section on Mice) and crabs.[214] While this is widely accepted, it is unknown if serotonin interacts directly or indirectly with parts of the brain influencing aggression and other behaviors.[206] Studies of serotonin levels show that they drastically increase and decrease during social interactions, and they generally correlate with inhibiting or inciting aggressive behavior.[215] The exact mechanism of serotonin influencing social behaviors is unknown, as pathways in the 5-HT system in various vertebrates can differ greatly.[206]

Response to stimuli
[edit]

Serotonin is important in environmental response pathways, along with other neurotransmitters.[216] Specifically, it has been found to be involved in auditory processing in social settings, as primary sensory systems are connected to social interactions.[217] Serotonin is found in the IC structure of the midbrain, which processes specie specific and non-specific social interactions and vocalizations.[217] It also receives acoustic projections that convey signals to auditory processing regions.[217] Research has proposed that serotonin shapes the auditory information being received by the IC and therefore is influential in the responses to auditory stimuli.[217] This can influence how an organism responds to the sounds of predatory or other impactful species in their environment, as serotonin uptake can influence aggression or social interaction.

Mood
[edit]

We can describe mood not as specific to an emotional status, but as associated with a relatively long-lasting emotional state. Serotonin's association with mood is most known for various forms of depression and bipolar disorders in humans.[207] Disorders caused by serotonergic activity potentially contribute to the many symptoms of major depression, such as overall mood, activity, suicidal thoughts and sexual and cognitive dysfunction. Selective serotonin reuptake inhibitors (SSRI's) are a class of drugs demonstrated to be an effective treatment in major depressive disorder and are the most prescribed class of antidepressants. SSRI's function is to block the reuptake of serotonin, making more serotonin available to absorb by the receiving neuron. Animals have been studied for decades in order to understand depressive behavior among species. One of the most familiar studies, the forced swimming test (FST), was performed to measure potential antidepressant activity.[207] Rats were placed in an inescapable container of water, at which point time spent immobile and number of active behaviors (such as splashing or climbing) were compared before and after a panel of anti-depressant drugs were administered. Antidepressants that selectively inhibit NE reuptake were shown to reduce immobility and selectively increase climbing without affecting swimming. However, results of the SSRI's also show reduced immobility but increased swimming without affecting climbing. This study demonstrated the importance of behavioral tests for antidepressants, as they can detect drugs with an effect on core behavior along with behavioral components of species.[207]

Growth and reproduction

[edit]

In the nematode C. elegans, artificial depletion of serotonin or the increase of octopamine cues behavior typical of a low-food environment: C. elegans becomes more active, and mating and egg-laying are suppressed, while the opposite occurs if serotonin is increased or octopamine is decreased in this animal.[33] Serotonin is necessary for normal nematode male mating behavior,[218] and the inclination to leave food to search for a mate.[219] The serotonergic signaling used to adapt the worm's behaviour to fast changes in the environment affects insulin-like signaling and the TGF beta signaling pathway,[220] which control long-term adaption.

In the fruit fly insulin both regulates blood sugar as well as acting as a growth factor. Thus, in the fruit fly, serotonergic neurons regulate the adult body size by affecting insulin secretion.[221][222] Serotonin has also been identified as the trigger for swarm behavior in locusts.[196] In humans, though insulin regulates blood sugar and IGF regulates growth, serotonin controls the release of both hormones, modulating insulin release from the beta cells in the pancreas through serotonylation of GTPase signaling proteins.[47] Exposure to SSRIs during pregnancy reduces fetal growth.[223]

Genetically altered C. elegans worms that lack serotonin have an increased reproductive lifespan, may become obese, and sometimes present with arrested development at a dormant larval state.[224][225]

[edit]

Serotonin is known to regulate aging, learning, and memory. The first evidence comes from the study of longevity in C. elegans.[220] During early phase of aging[vague], the level of serotonin increases, which alters locomotory behaviors and associative memory.[226] The effect is restored by mutations and drugs (including mianserin and methiothepin) that inhibit serotonin receptors. The observation does not contradict with the notion that the serotonin level goes down in mammals and humans, which is typically seen in late but not early[vague] phase of aging.

Biochemical mechanisms

[edit]

Biosynthesis

[edit]
On top an L-tryptophan molecule with an arrow down to a 5-HTP molecule. Tryptophan hydroxylase catalyses this reaction with help of O2 and tetrahydrobiopterin, which becomes water and dihydrobiopterin. From the 5-HTP molecule goes an arrow down to a serotonin molecule. Aromatic L-amino acid decarboxylase or 5-Hydroxytryptophan decarboxylase catalyses this reaction with help of pyridoxal phosphate. From the serotonin molecule goes an arrow to a 5-HIAA molecule at the bottom of the image. Monoamine oxidase catalyses this reaction, in the process O2 and water is consumed, and ammonia and hydrogen peroxide is produced.
The pathway for the synthesis of serotonin from tryptophan

In animals and humans, serotonin is synthesized from the amino acid L-tryptophan by a short metabolic pathway consisting of two enzymes, tryptophan hydroxylase (TPH) and aromatic amino acid decarboxylase (DDC), and the coenzyme pyridoxal phosphate. The TPH-mediated reaction is the rate-limiting step in the pathway.

TPH has been shown to exist in two forms: TPH1, found in several tissues, and TPH2, which is a neuron-specific isoform.[227]

Serotonin can be synthesized from tryptophan in the lab using Aspergillus niger and Psilocybe coprophila as catalysts. The first phase to 5-hydroxytryptophan would require letting tryptophan sit in ethanol and water for 7 days, then mixing in enough HCl (or other acid) to bring the pH to 3, and then adding NaOH to make a pH of 13 for 1 hour. Aspergillus niger would be the catalyst for this first phase. The second phase to synthesizing tryptophan itself from the 5-hydroxytryptophan intermediate would require adding ethanol and water, and letting sit for 30 days this time. The next two steps would be the same as the first phase: adding HCl to make the pH = 3, and then adding NaOH to make the pH very basic at 13 for 1 hour. This phase uses the Psilocybe coprophila as the catalyst for the reaction.[228]

Process

Serotonin taken orally does not pass into the serotonergic pathways of the central nervous system, because it does not cross the blood–brain barrier.[9] However, tryptophan and its metabolite 5-hydroxytryptophan (5-HTP), from which serotonin is synthesized, do cross the blood–brain barrier. These agents are available as dietary supplements and in various foods, and may be effective serotonergic agents.

One product of serotonin breakdown is 5-hydroxyindoleacetic acid (5-HIAA), which is excreted in the urine. Serotonin and 5-HIAA are sometimes produced in excess amounts by certain tumors or cancers, and levels of these substances may be measured in the urine to test for these tumors.

Analytical chemistry

[edit]

Indium tin oxide is recommended for the electrode material in electrochemical investigation of concentrations produced, detected, or consumed by microbes.[229] A mass spectrometry technique was developed in 1994 to measure the molecular weight of both natural and synthetic serotonins.[230]

History and etymology

[edit]

It had been known to physiologists for over a century that a vasoconstrictor material appears in serum when blood was allowed to clot.[231] In 1935, Italian Vittorio Erspamer, working in Pavia, showed an extract from enterochromaffin cells made intestines contract. Some believed it contained adrenaline, but two years later, Erspamer was able to show it was a previously unknown amine, which he named "enteramine".[232][233] In 1948, Maurice M. Rapport, Arda Green, and Irvine Page of the Cleveland Clinic discovered a vasoconstrictor substance in blood serum, and since it was a serum agent affecting vascular tone, they named it serotonin.[234]

In 1952, enteramine was shown to be the same substance as serotonin, and as the broad range of physiological roles was elucidated, the abbreviation 5-HT of the proper chemical name 5-hydroxytryptamine became the preferred name in the pharmacological field.[235] Synonyms of serotonin include: 5-hydroxytriptamine, enteramine, substance DS, and 3-(β-aminoethyl)-5-hydroxyindole.[236] In 1953, Betty Twarog and Page discovered serotonin in the central nervous system.[237] Page regarded Erspamer's work on Octopus vulgaris, Discoglossus pictus, Hexaplex trunculus, Bolinus brandaris, Sepia, Mytilus, and Ostrea as valid and fundamental to understanding this newly identified substance, but regarded his earlier results in various models – especially those from rat blood – to be too confounded by the presence of other bioactive chemicals, including some other vasoactives.[238]

Effects in humans

[edit]

Serotonin, given orally at a dose of 100 mg, produced effects in humans including blood pressure changes, abdominal cramps, muscle aches, and a feeling of sedation.[239][240][241] In contrast to psychedelic drugs like LSD, no hallucinogenic effects were reported.[239][240][241] In other studies, serotonin, at low intravenous doses of 2 to 6 mg, had no effects on electroencephalogram (EEG) readings in humans.[242] In accordance with the preceding findings, it has been stated that administration of serotonin in humans produces no psychoactive effects that cannot be attributed to anxiety by its profound peripheral adverse effects including circulatory disturbance, other autonomic effects, and vomiting.[242][243] Intracerebroventricular injection of serotonin has been studied in patient with severe psychiatric conditions, but little information about its psychoactive effects is provided.[243][244]

It is thought that exogenous serotonin is too hydrophilic to cross the blood–brain barrier and has too poor of metabolic stability due to rapid metabolism by monoamine oxidase (MAO) such that it cannot produce drug-like central effects in humans with peripheral administration.[240][245] However, close analogues of serotonin that are more lipophilic and metabolically stable, like bufotenin (N,N-dimethylserotonin), 5-MeO-DMT (N,N,O-trimethylserotonin), and 5-MeO-AMT (α,O-dimethylserotonin), among many others, are active and produce pronounced centrally mediated effects in humans.[245][246] These drugs are non-selective serotonin receptor agonists like serotonin and are serotonergic psychedelics due to activation of the serotonin 5-HT2A receptor.[245][247][246] α-Methylserotonin is well-studied in preclinical research, but is not known to have been tested in humans.[245]

Notes

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Serotonin, also known as 5-hydroxytryptamine (5-HT), is a that plays a central role in regulating mood, , , , and various physiological processes throughout the body. It is synthesized from the L-tryptophan through a two-step enzymatic process involving and , primarily in serotonergic neurons of the and enterochromaffin cells of the . Approximately 90-95% of the body's serotonin is produced and stored in the gut, with the remainder distributed in the (CNS), platelets, and , where it serves as a precursor to . In the CNS, serotonin modulates neural activity across a wide range of neuropsychological processes, including emotion, , and sensory , by acting on seven families of receptors (5-HT1 through 5-HT7), most of which are G-protein-coupled receptors that influence cyclic AMP levels, intracellular calcium, or activity. Peripherally, it contributes to gastrointestinal motility, platelet aggregation for , cardiovascular tone through or , and endocrine functions such as milk ejection in mammary glands. Beyond , serotonin facilitates non-neuronal processes like via platelet-derived signaling and autocrine regulation in developing tissues. Dysregulation of serotonin signaling is implicated in numerous disorders, including depression, anxiety, and obsessive-compulsive disorder, where reduced levels or impaired transmission are common; conversely, excessive serotonin can lead to , a potentially life-threatening condition characterized by autonomic instability and neuromuscular abnormalities. Therapeutic interventions, such as selective serotonin reuptake inhibitors (SSRIs), enhance serotonergic activity by blocking the (SERT), thereby alleviating symptoms in mood disorders. Its evolutionary conservation underscores its fundamental role in integrative functions, from basic to complex behaviors.

Structure and Chemistry

Molecular Structure

Serotonin, chemically known as 5-hydroxytryptamine (5-HT), possesses the molecular formula C₁₀H₁₂N₂O and the systematic IUPAC name 3-(2-aminoethyl)-1H-indol-5-ol. The core structure is an ring—a bicyclic aromatic system formed by the fusion of a ring and a five-membered ring—with a hydroxyl (-OH) group substituted at the 5-position on the benzene moiety and an side chain (-CH₂CH₂NH₂) attached at the 3-position of the ring. This arrangement positions the polar functional groups away from the hydrophobic indole core, influencing intermolecular interactions. The indole ring exhibits characteristic aromatic bond lengths and angles, with C-C bonds averaging 1.39 and C-N bonds around 1.37 in the fused system, contributing to its planarity and electron delocalization. The side chain connects via a C3-Cα bond of approximately 1.50 , followed by Cα-Cβ and Cβ-N bonds of 1.51 and 1.46 , respectively, allowing rotational freedom around these single bonds. Key dihedral angles, such as the C3-Cα-Cβ-N torsion (around -62° in the folded conformation), enable multiple low-energy conformers where the folds back toward the indole plane or extends outward, with the folded form often stabilized by intramolecular hydrogen bonding between the and hydroxyl groups. Serotonin is achiral, lacking stereocenters, though its flexible permits rapid interconversion between conformers at physiological temperatures. The hydroxyl group at position 5 imparts phenolic character, enhancing polarity through donation and acceptance, while the primary provides basicity and additional hydrogen bonding capability, both facilitating solubility in aqueous environments despite the nonpolar backbone. These functional groups are critical for serotonin's biochemical roles, as the polar termini enable specific interactions with biological targets. Structurally, serotonin derives its scaffold from (3-(2-aminoethyl)-1H-), which lacks the 5-hydroxyl substitution, rendering tryptamine less polar and more hydrophobic. In contrast, (N-acetyl-5-methoxytryptamine) builds upon serotonin's framework through N-acetylation of the and O-methylation of the hydroxyl, increasing for its role as a . These relations highlight serotonin's position as a key intermediate in indoleamine chemistry.

Crystal Structure

The crystal structure of serotonin, or 5-hydroxytryptamine (5-HT), was first determined in 2022 through single-crystal diffraction analysis of a sample crystallized from a solution. This structure reveals serotonin in its neutral form, with one in the asymmetric unit adopting a gauche–gauche conformation for the ethylamino , characterized by torsion angles of C7—C8—C9—C10 = −64.2(3)° and C8—C9—C10—N2 = −61.9(2)°. The crystals belong to the orthorhombic P2₁2₁2₁, with parameters a = 8.2248(6) Å, b = 8.7542(6) Å, c = 13.0712(10) Å, and a volume of V = 941.15(12) ų (Z = 4). In the lattice, serotonin molecules are linked via intermolecular hydrogen bonds involving the hydroxyl and groups, forming a three-dimensional network that enhances structural stability; no π–π stacking interactions are observed. Key hydrogen bonding geometries include:
  • O1—H1⋯N2: D⋯A = 2.636(2) Å, ∠D—H⋯A = 170(3)°
  • N1—H1A⋯O1: D⋯A = 2.967(2) Å, ∠D—H⋯A = 169(2)°
  • N2—H2B⋯O1: D⋯A = 3.092(3) Å, ∠D—H⋯A = 168(2)°
These interactions, with donor–acceptor distances typical for strong hydrogen bonds (2.6–3.1 Å), contribute to the cohesive packing in the crystal. No polymorphic forms of serotonin have been reported to date, though the determined structure serves as a foundational reference for pharmaceutical formulations, aiding in the design of stable solid-state forms and understanding intermolecular forces relevant to drug processing and bioavailability.

Physical and Chemical Properties

Serotonin appears as a to off-white crystalline solid at and has a of 167–168 °C. The compound exhibits moderate solubility in , approximately 20 g/L (20 mg/mL) at neutral , owing to its polar hydroxyl and amine groups (primarily in protonated form), but shows higher solubility in alcohols such as and , as well as in DMSO. Its ionization is governed by experimental pKa values of approximately 9.8 for the conjugate acid of the aliphatic amine group and 11.1 for the phenolic hydroxyl group, enabling at physiological to form a cationic that enhances aqueous solubility compared to the neutral form. Serotonin is hygroscopic and prone to oxidation, particularly in neutral or alkaline solutions where it undergoes auto-oxidation to yield dimers and other colored degradation products, necessitating storage under inert conditions or with antioxidants for stability. It also possesses intrinsic properties under excitation, with absorption maximum near 297 nm and emission peak at approximately 340 nm, attributed to the ring system. In terms of reactivity, serotonin engages in protonation/deprotonation equilibria dominated by the group, shifting between cationic, zwitterionic, and neutral forms based on . The electron-rich ring undergoes primarily at the 3-position, facilitating reactions with oxidants or alkylating agents, though such interactions are moderated by the adjacent hydroxyl substituent.

Biosynthesis and Metabolism

Biosynthesis Pathway

Serotonin is biosynthesized from the L- through a two-step enzymatic pathway that occurs primarily in serotonergic neurons of the , enterochromaffin cells of the , and pinealocytes. The initial and rate-limiting step involves the of L- at the 5-position to form 5-hydroxytryptophan (5-HTP), catalyzed by (TPH). This reaction requires the cofactors (BH4), molecular oxygen, and ferrous iron (Fe2+), with BH4 serving as the in the monooxygenation . The TPH-mediated step is tightly regulated and determines the overall capacity for serotonin production, as it commits tryptophan to the serotonergic pathway. The second step entails the of 5-HTP to serotonin (5-hydroxytryptamine, 5-HT), facilitated by (AADC, also known as DDC). This pyridoxal 5'-phosphate (PLP)-dependent enzyme rapidly converts 5-HTP, ensuring efficient production of the without significant accumulation of the intermediate. AADC is widely expressed and not rate-limiting, allowing the pathway to proceed swiftly once 5-HTP is available. TPH exists as two distinct isoforms encoded by separate genes, exhibiting tissue-specific expression that underlies the compartmentalization of serotonin synthesis. TPH1 is predominantly found in peripheral tissues, including enterochromaffin cells of the gut mucosa, , and , where it supports local serotonin production for non-neuronal functions. In contrast, TPH2 is the primary isoform in the , particularly in serotonergic neurons, and in enteric neurons of the gut, driving central and enteric serotonergic signaling. This isoform specificity ensures that neuronal and peripheral serotonin pools are synthesized independently, with minimal overlap in regulation. While the TPH-AADC pathway represents the dominant route, minor alternative mechanisms can contribute to serotonin production under specific conditions. For instance, (PAH) has been shown to generate trace amounts of 5-HTP from in certain tissues, such as the liver and in mice, though this is negligible compared to the canonical pathway. Additionally, the availability of L-tryptophan as a dietary directly modulates biosynthesis rates, as plasma tryptophan levels influence its across the blood-brain barrier and uptake into peripheral cells, thereby affecting TPH substrate saturation.

Degradation and Reuptake

Serotonin levels in the synaptic cleft and extracellular spaces are tightly regulated through enzymatic degradation and transporter-mediated , preventing overstimulation of receptors and maintaining signaling . The primary degradation pathway involves oxidative catalyzed by (MAO-A), which converts serotonin (5-hydroxytryptamine, 5-HT) into 5-hydroxyindoleacetaldehyde; this intermediate is then rapidly oxidized by (ALDH) to form (5-HIAA), the major metabolite. This process predominantly occurs in the liver, though initial can take place in the synaptic cleft following release. Reuptake provides a key recycling mechanism, with the (SERT), encoded by the SLC6A4 gene, facilitating the sodium- and -dependent transport of from the synaptic cleft back into presynaptic neurons. SERT operates via an alternating access mechanism, binding extracellular sodium and ions to stabilize uptake, thereby terminating its postsynaptic effects and allowing repackaging into vesicles. This high-affinity, low-capacity process is essential for rapid clearance and is the target of selective reuptake inhibitors (SSRIs) used in treating mood disorders. In addition to neuronal reuptake, extraneuronal uptake contributes to serotonin clearance, primarily mediated by low-affinity organic cation transporters (OCTs), such as OCT3 (encoded by SLC22A3). OCT3 facilitates sodium- and chloride-independent transport of serotonin into non-neuronal cells, particularly in regions like the hippocampus where it helps buffer extracellular levels when SERT activity is reduced. The end product of degradation, 5-HIAA, is excreted primarily through the kidneys, with urinary levels serving as a reliable for systemic serotonin turnover; normal 24-hour ranges from 3 to 15 mg, and elevations are indicative of conditions like . This urinary pathway reflects overall metabolic flux, as 5-HIAA is cleared from circulation via glomerular filtration.

Post-Translational Modifications

Serotonylation represents a key where serotonin acts as a covalent donor to residues on target proteins, catalyzed primarily by 2 (TG2). This process, distinct from serotonin's role as a , enables serotonin to modulate protein function directly, particularly in non-neuronal cells. TG2 facilitates the formation of an between the primary amine group of serotonin and the γ-carboxamide of , thereby altering the target's activity, localization, or stability. A prominent example involves the RhoA, where serotonylation enhances its activation by promoting GTP binding and membrane association, crucial for cytoskeletal rearrangements. In vascular cells, TG2-mediated RhoA serotonylation initially drives contraction but subsequently targets RhoA for ubiquitination and proteasomal degradation, leading to RhoA depletion and inhibition of sustained contraction. This biphasic regulation underscores serotonylation's role in fine-tuning cellular responses to serotonin. Inhibition of TG2 or serotonin uptake disrupts this modification, reducing RhoA activity and associated cellular processes like proliferation. In biological contexts, serotonylation contributes to platelet activation by modifying RhoA and Rab4a, facilitating α-granule and dense granule release essential for . Similarly, in vascular tissues, it influences endothelial and function, with dysregulation implicated in where elevated serotonylation promotes pathological proliferation and . These modifications highlight serotonin's non-transmission roles in peripheral systems, extending its impact beyond the . Beyond serotonylation, post-translational modifications of serotonin-related enzymes are less common but include phosphorylation of tryptophan hydroxylase (TPH), the rate-limiting enzyme in serotonin . at specific serine residues activates TPH2, the neuronal isoform, enhancing its catalytic efficiency and stability in response to calcium-calmodulin signaling. These enzyme modifications primarily regulate serotonin production rather than serotonin itself.

Cellular and Receptor Mechanisms

Serotonin Receptors

Serotonin receptors, also known as 5-HT receptors, comprise a diverse family of proteins that mediate the effects of serotonin (5-hydroxytryptamine, 5-HT) in the central and peripheral nervous systems. These receptors are classified into seven main families (5-HT1 to 5-HT7), with a total of 14 subtypes identified based on pharmacological, structural, and transductional characteristics. All except the 5-HT3 receptor belong to the (GPCR) superfamily, featuring seven transmembrane domains, while 5-HT3 is a . This classification was established through and functional studies in the late 1980s and 1990s. The 5-HT1 family includes five subtypes: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F, all Gi/o-coupled GPCRs that inhibit and reduce cyclic AMP levels. The 5-HT2 family consists of 5-HT2A, 5-HT2B, and 5-HT2C, which are Gq/11-coupled GPCRs activating and increasing and diacylglycerol. The 5-HT3 receptor is a pentameric ligand-gated cation channel permeable to Na+, K+, and Ca2+, leading to rapid . The remaining families—5-HT4, 5-HT5 (subtypes 5-HT5A and 5-HT5B), 5-HT6, and 5-HT7—are Gs-coupled GPCRs (except 5-HT5, where coupling is Gi/o-like but effectors are less defined) that stimulate . Tissue distributions vary widely: for instance, 5-HT1A is prominent in the hippocampus, , , and cortex; 5-HT2A in the , , and ; 5-HT3 in peripheral ganglia, , and ; 5-HT1B in vascular smooth muscle and ; and 5-HT4 in the and brain regions like the . Ligand binding affinities differ across subtypes, influencing their selectivity for serotonin and synthetic /antagonists. Serotonin itself binds with high affinity (Ki < 10 nM) to most GPCRs, such as 5-HT1A (Ki ≈ 1-3 nM for 8-OH-DPAT ) and 5-HT2A (Ki < 10 nM). For 5-HT1B/5-HT1D, shows moderate affinity (Ki = 20-30 nM). The 5-HT3 receptor has lower affinity for serotonin (Ki ≈ 500 nM), with selective like 2-methyl-5-HT exhibiting higher potency. In the 5-HT6 and 5-HT7 subtypes, and 5-carboxamidotryptamine (5-CT) bind with subnanomolar to low nanomolar affinities (e.g., methiothepin Ki = 0.4 nM for 5-HT6). These affinities are determined via radioligand binding assays using tritiated or iodinated probes.
Receptor FamilySubtypesClass & CouplingExample Tissue DistributionExample Ligand Affinity (Ki)
5-HT15-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1FGPCR, Gi/o (↓ cAMP)Hippocampus, raphe, vasculature8-OH-DPAT: 1-3 nM (5-HT1A); : 20-30 nM (5-HT1B)
5-HT25-HT2A, 5-HT2B, 5-HT2CGPCR, Gq/11 (↑ IP3/DAG), , : <10 nM (5-HT2A)
5-HT35-HT3A, 5-HT3B (Na+/K+/Ca2+), , GI tract5-HT: ≈500 nM; 2-methyl-5-HT: higher potency
5-HT45-HT4 (splice variants)GPCR, Gs (↑ cAMP)GI tract, , heart5-HT: <10 nM
5-HT55-HT5A, 5-HT5BGPCR, Gi/o-like (↓ cAMP)Cortex, , hippocampus5-HT: low nM range
5-HT65-HT6GPCR, Gs (↑ cAMP), Methiothepin: 0.4 nM
5-HT75-HT7 (splice variants)GPCR, Gs (↑ cAMP), , vasculature5-CT: subnanomolar
Genetic variations in serotonin receptor genes contribute to functional diversity and disease susceptibility. For example, the HTR2A gene encoding 5-HT2A features the T102C polymorphism (rs6313), which alters receptor expression and has been linked to mood disorders without changing affinity. The HTR1A gene (5-HT1A) C-1019G polymorphism (rs6295) in the promoter region reduces expression, influencing anxiety and response. Splice variants are common, such as in 5-HT4 (long and short isoforms differing in C-terminal tails) and 5-HT7 (multiple isoforms affecting desensitization). The 5-HT1D receptor arises from two genes (HTR1Dα on and HTR1Dβ on ), leading to species-specific subtype distinctions. These polymorphisms are studied via association analyses in psychiatric cohorts.

Intracellular Signaling Pathways

Serotonin receptors mediate intracellular signaling primarily through G-protein-coupled mechanisms for most subtypes, with the exception of the ionotropic . Upon binding, these receptors activate specific G-proteins that transduce signals via second messenger systems, influencing cellular processes such as ion flux, activity, and . The diversity in coupling allows serotonin to elicit varied responses across cell types. The 5-HT1 receptor family (including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F subtypes) couples to Gi/o proteins, which inhibit adenylyl cyclase and reduce cyclic AMP (cAMP) levels, thereby decreasing protein kinase A (PKA) activity. This pathway modulates potassium channel opening and calcium channel closure, contributing to hyperpolarization in neurons. Similarly, the 5-HT5 family (5-HT5A and 5-HT5B) also couples to Gi/o, leading to adenylyl cyclase inhibition and cAMP reduction, though functional details remain less characterized due to limited expression data. In contrast, the 5-HT2 family (5-HT2A, 5-HT2B, and 5-HT2C) activates Gq/11 proteins, stimulating (PLC) to hydrolyze (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium stores, while DAG activates (PKC), promoting downstream effects like gene transcription. The 5-HT4, 5-HT6, and 5-HT7 receptors couple to Gs proteins, enhancing activity and elevating cAMP levels, which activates PKA and influences cyclic nucleotide-gated channels. These Gs-mediated pathways are prominent in modulating neuronal excitability and . The 5-HT3 receptor functions as a ligand-gated ion channel, distinct from the G-protein-coupled families. Binding of serotonin opens the channel, permitting influx of sodium and calcium ions alongside potassium efflux, resulting in rapid depolarization and excitation of the target cell. This ionotropic mechanism lacks second messenger involvement but can indirectly influence other pathways through calcium-dependent processes. Beyond canonical G-protein signaling, serotonin receptors exhibit crosstalk with non-G-protein pathways, often via scaffold proteins. For instance, the 5-HT2A receptor recruits β-arrestin2 to activate the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) cascade, independent of Gq/11, facilitating proliferation and survival signals in certain cell types. Similarly, 5-HT2C receptors engage β-arrestins for ERK1/2 phosphorylation, highlighting biased agonism where ligands preferentially activate specific effectors. These interactions underscore the multifunctional nature of receptor signaling. Receptor desensitization and internalization are critical regulatory steps, primarily mediated by G-protein-coupled receptor kinases (GRKs) and β-arrestins. Activated receptors are phosphorylated by GRKs (e.g., GRK2 for 5-HT4), recruiting β-arrestins that uncouple G-proteins, halting signaling. This is followed by clathrin-mediated , where β-arrestins act as adaptors for internalization; for 5-HT2A, this process is agonist-dependent and cell-type specific, while 5-HT4 isoforms show variable β-arrestin involvement based on palmitoylation. Internalized receptors may recycle or degrade, tuning signaling duration.

Termination of Signaling

Serotonin signaling, primarily mediated through G protein-coupled receptors (GPCRs), is tightly regulated to prevent prolonged activation and maintain cellular . Termination of signaling occurs through multiple mechanisms that act at the receptor level, including desensitization, internalization, feedback inhibition via autoreceptors, and modulation by regulatory proteins. These processes ensure precise temporal control, allowing rapid adaptation to fluctuating serotonin levels. Desensitization of serotonin receptors involves phosphorylation by specific kinases, which uncouples the receptor from its associated G-proteins and attenuates downstream signaling. For instance, (PKA) and (PKC) phosphorylate residues on receptors such as the 5-HT1A subtype, leading to reduced coupling efficiency with Gαi/o proteins and inhibition of activity. This phosphorylation-dependent desensitization is a key early-phase regulatory step, observed in both recombinant and native systems, where prolonged exposure triggers kinase activation via second messenger pathways. Additionally, G protein-coupled receptor kinases (GRKs) contribute to homologous desensitization by phosphorylating activated receptors, facilitating β-arrestin binding and further signal termination. Following desensitization, many serotonin receptors undergo internalization through clathrin-mediated , which removes them from the plasma membrane and sequesters signaling. Agonist-bound receptors, often phosphorylated by GRKs, recruit β-arrestins that serve as adaptors for clathrin-coated pits, promoting rapid via dynamin-dependent vesicle formation. Internalized receptors can then follow one of two fates: back to the cell surface after in early endosomes, which allows resensitization, or trafficking to lysosomes for proteolytic degradation, resulting in downregulation of receptor density. This is particularly prominent for 5-HT1A and 5-HT2A receptors, where not only terminates signaling but also influences long-term receptor availability. Feedback inhibition provides an additional layer of control through presynaptic s, which sense extracellular serotonin and limit further release. The 5-HT1A , located on serotonergic neurons in the , couples to Gαi/o proteins to hyperpolarize the cell via GIRK channels, thereby reducing firing rates and serotonin . This loop is crucial for preventing excessive serotonin accumulation in the and is activated rapidly upon increased serotonin levels, modulating the overall tone of serotonergic transmission. Regulators of signaling (RGS) proteins further accelerate signal termination by enhancing the intrinsic activity of Gα subunits. RGS proteins, such as RGS4 and RGS6, interact with the Gαi/o subunits activated by 5-HT1A receptors, catalyzing to promote the return to the inactive GDP-bound state and rapidly quenching effector activation like inhibition. In serotonergic systems, RGS modulation fine-tunes signaling duration, with implications for behaviors influenced by serotonin, such as anxiety and mood .

Physiological Roles

Functions in the Nervous System

Serotonin is primarily synthesized in the serotonergic neurons of the raphe nuclei, a group of midline structures spanning the brainstem from the midbrain to the medulla. These nuclei, including the dorsal and median raphe, generate the majority of serotonergic projections in the central nervous system, providing over 80% of the 5-HT innervation to target regions. The dorsal raphe nucleus sends ascending projections to forebrain areas such as the cortex, hippocampus, and amygdala, while both dorsal and median raphe contribute to descending pathways reaching the brainstem and spinal cord, enabling diffuse modulation of neural circuits. This extensive arborization allows serotonin to influence a broad array of physiological processes through volume transmission and synaptic release. At the ultrastructural level, serotonin is packaged and stored in dense-core vesicles (DCVs) within the soma, dendrites, and axon terminals of serotonergic neurons. These vesicles, typically 80-120 nm in diameter, contain serotonin along with associated proteins and are distinct from smaller clear synaptic vesicles. Upon neuronal , serotonin release from DCVs occurs via calcium-dependent , where influx of Ca²⁺ through voltage-gated channels triggers vesicle fusion with the plasma membrane, often in response to trains. This mechanism supports both somatic and terminal release, contributing to the neuromodulatory effects of serotonin across neural networks. As a , serotonin modulates , enhancing or suppressing and depression in regions like the hippocampus and to influence learning, , and adaptive behaviors.00821-5) It regulates sleep-wake cycles, with raphe serotonergic neurons promoting wakefulness and suppressing rapid eye movement (REM) sleep through projections to arousal centers in the and . Serotonin also controls via activation of 5-HT₂C receptors in hypothalamic neurons, where it enhances signals and reduces food intake by inhibiting orexigenic pathways. In mood regulation, postsynaptic 5-HT₁A receptor stimulation in the and hippocampus reduces anxiety by dampening excessive excitatory transmission. Conversely, diminished serotonergic tone, often linked to low extracellular serotonin levels, is associated with depressive states, impairing emotional processing and resilience.

Functions in the Gastrointestinal Tract

Approximately 90% of the body's serotonin is produced and stored in the , primarily by enterochromaffin (EC) cells in the intestinal mucosa, underscoring its dominant role in gut . These EC cells synthesize serotonin from the L-tryptophan using the enzyme 1 (TPH1), which is distinct from the TPH2 isoform used in the . Upon synthesis, serotonin is stored in EC cell granules and released into the gut lumen or in response to mechanical stimuli, such as luminal distension or stroking of the mucosa, and chemical stimuli, including nutrients like glucose and fatty acids or bacterial toxins. This release activates nearby enteric neurons and epithelial cells via specific serotonin receptors, such as 5-HT3 and 5-HT4 subtypes, to coordinate local reflexes. Serotonin plays a central role in regulating motility, facilitating and segmentation contractions essential for propulsion of luminal contents. Activation of 5-HT4 receptors on enteric neurons enhances release, promoting contraction and increasing peristaltic activity, as evidenced by the motility-enhancing effects of 5-HT4 agonists in models and studies. Conversely, 5-HT3 receptors on sensory afferents within the detect serotonin release and initiate reflex arcs that amplify propulsive movements, while also contributing to visceral hypersensitivity and signals transmitted to the . Dysregulation of these pathways is implicated in disorders like , where altered serotonin signaling disrupts normal motility patterns. In addition to motility, serotonin stimulates intestinal secretion, particularly of chloride ions and water, which aids in digestion and fluid balance. Released serotonin acts on 5-HT4 receptors located on enterocytes and submucosal secretomotor neurons, triggering cyclic AMP-dependent pathways that open chloride channels and drive fluid secretion into the lumen. This mechanism is crucial for neutralizing gastric acid and facilitating nutrient absorption, with studies showing that 5-HT4 activation increases secretory responses in isolated intestinal preparations. Serotonin also interacts bidirectionally with the gut microbiome, influencing microbial composition and vice versa through the gut-brain axis. Peripheral serotonin modulates gut flora by enhancing nutrient uptake and altering microbial diversity, as peripheral TPH1 mice exhibit and impaired microbiota-dependent functions. Conversely, gut bacteria regulate serotonin production; for instance, produced by like Candida species or spp. stimulate TPH1 expression in EC cells, increasing colonic serotonin levels, while germ-free mice display significantly reduced serotonin compared to conventionalized counterparts. Recent research highlights how , such as , boost serotonin biosynthesis via microbial metabolites like , potentially ameliorating GI disorders and influencing central serotonin signaling through vagal pathways.

Functions in Other Peripheral Systems

In the cardiovascular system, serotonin released from activated platelets acts as a potent vasoconstrictor through of 5-HT2A and 5-HT2B receptors on vascular cells, contributing to platelet aggregation and in diseased vessels. This vasoconstrictive effect is particularly pronounced in conditions like pulmonary arterial hypertension, where platelet-derived serotonin exacerbates vascular remodeling. Additionally, serotonin serves as a during cardiac development, promoting proliferation and differentiation of cardiac cells via the 5-HT2B receptor expressed in embryonic heart tissues. In the respiratory system, serotonin contributes to bronchoconstriction in asthma through 5-HT2A receptor activation on airway smooth muscle, enhancing airway hyperresponsiveness and inflammation. Elevated serotonin levels have been observed in asthmatic patients, correlating with disease severity and exacerbation. Furthermore, serotonin signaling via 5-HT2A and 5-HT2B receptors promotes mucus hypersecretion in the airways, particularly in response to environmental irritants like cigarette smoke or , leading to impaired . Serotonin can inhibit proliferation, reducing bone formation and contributing to . This inhibitory effect is linked to elevated peripheral serotonin levels, as seen in conditions like , where hyper-serotonemia from enterochromaffin cells suppresses osteoblast activity and exacerbates bone loss. The 5-HT2B receptor mediates serotonin's effects on osteoblast proliferation, and its deletion in animal models leads to age-related , underscoring its role in maintaining bone mass. Beyond these systems, serotonin drives skin via 5-HT2B receptor activation on , promoting deposition and sclerotic remodeling following vascular . In , serotonin modulates through the 5-HT2B receptor, stimulating free release during to support , though excessive signaling contributes to in . Similarly, in the lungs, serotonin aggravates by enhancing and activation via 5-HT2B, as evidenced in bleomycin-induced models where receptor blockade attenuates deposition and tissue scarring.

Developmental and Comparative Biology

Roles in Organ Development and Growth

Serotonin plays a critical role in embryonic development, particularly through the activity of its synthesizing enzymes, and TPH2. TPH1, predominantly expressed in peripheral tissues, and TPH2, specific to serotonergic neurons, facilitate serotonin production essential for processes like cell migration. In murine models, maternal serotonin derived from TPH1 supports the migration of cranial cells, which are vital for forming structures such as the face and heart; disruption of this pathway leads to craniofacial and cardiovascular defects. Similarly, in embryos, serotonin synthesized via TPH2 is required for proper morphogenesis, a process involving derivatives, highlighting its conserved role in embryogenesis. In cardiac development, serotonin signaling via the is indispensable for formation. Activation of promotes the proliferation and differentiation of cardiac cells into valvular cushion ; genetic of this receptor in mice results in hypoplastic ventricles and defective valve leaflets, underscoring its necessity for proper cardiac . Serotonin also exhibits growth factor-like activity in tissue patterning. During early embryogenesis in chick embryos, serotonin uptake is observed in the myocardium and at the 3–5 stage, coinciding with formation, and exogenous serotonin enhances actomyosin contractility to promote axis extension and boundary delineation in , suggesting analogous mechanisms in somitogenesis. In bone development, peripheral serotonin inhibits proliferation through Htr1b receptor activation and CREB-mediated pathways, thereby suppressing formation and remodeling; elevated gut-derived serotonin, as seen in mutant mice, reduces bone mass by limiting activity. Serotonin's influence extends to reproductive organ development. In mammalian ovaries, serotonin promotes follicular maturation by upregulating expression and enhancing proliferation via (SERT) activity; inhibition of SERT impairs competence and follicle growth in mouse models. In some species, including humans and bivalves, serotonin directly stimulates by inducing tyrosine phosphorylation and flagellar hyperactivation, facilitating fertilization; for instance, expression in human correlates with increased progressive motility. These effects are mediated by local serotonergic components in gametes, independent of input. Beyond embryogenesis, serotonin modulates tissue regeneration, particularly , by stimulating proliferation. In post-thermal injury models, serotonin released from platelets reduces and boosts in human dermal fibroblasts via signaling, accelerating re-epithelialization and deposition; topical serotonin or SSRIs enhance this process in wounds by promoting migration and activation. This regenerative role parallels its developmental functions, where receptor-mediated pathways, as detailed in intracellular signaling discussions, drive cellular responses without overlapping adult maintenance roles.

Occurrence in Non-Vertebrates

Serotonin is present in various invertebrates, where it modulates diverse physiological processes beyond neural signaling. In nematodes such as Caenorhabditis elegans, serotonin acts through specific 5-HT receptors, including the SER-7 receptor, to stimulate egg-laying behavior by enhancing pharyngeal pumping and vulval muscle contraction. In decapod crustaceans like crayfish and shrimp, serotonin promotes molting by influencing the Y-organs, the endocrine glands responsible for ecdysteroid synthesis, thereby accelerating tissue regeneration and growth cycles. Insects also utilize serotonin to regulate feeding; for instance, in ants such as Camponotus mus, exogenous serotonin depresses sucrose intake in a dose-dependent manner, reducing feeding rates and potentially modulating colony foraging dynamics. Additionally, serotonin occurs in invertebrate venoms, including those of social wasps, where it contributes to the stinging sensation and inflammatory response upon envenomation. In and fungi, serotonin is biosynthesized from the amino acid via enzymes such as decarboxylase and 5-hydroxylase, mirroring aspects of animal pathways but serving non-neural roles. In like (), serotonin accumulation enhances tolerance to abiotic stresses, including , by improving , , and spikelet fertility under water-limited conditions. Exogenous application of serotonin to seedlings mitigates drought-induced oxidative damage by boosting activities and soluble sugar content, thereby sustaining growth and yield. In fungi, particularly hallucinogenic mushrooms of the genus, serotonin-related pathways derive from , with serotonin acting as an intermediate precursor that links to the production of psychoactive compounds influencing host serotonin receptors. Unicellular organisms also exhibit serotonin involvement in key functions. In bacteria like , serotonin is taken up and activates pathways, enhancing expression, formation, and interkingdom signaling with host cells. Protozoans such as Tetrahymena pyriformis produce and respond to serotonin, which regulates ciliary motility through actomyosin contractility, influencing and locomotion essential for survival in aquatic environments. Non-neural roles of serotonin extend to immune modulation in like mollusks. In bivalves such as oysters (Crassostrea gigas), serotonin participates in neuroendocrine-immune interactions, protecting against pathogen invasion by altering hemocyte activity and redox balance during environmental stress.

Evolutionary Conservation

Serotonin, or 5-hydroxytryptamine (5-HT), exhibits deep evolutionary roots, with its biosynthetic pathway originating well before the emergence of metazoans. The precursor molecule L-tryptophan and its metabolic pathways, including to form 5-HT, are present in prokaryotes such as , where enzymes like (AADC) homologs facilitate similar conversions, indicating a prokaryotic origin dating back billions of years. This ancient conservation suggests that 5-HT initially functioned in basic cellular processes, such as stress responses or environmental sensing in unicellular organisms. While specific 5-HT receptors are absent in prokaryotes, the (GPCR) superfamily to which they belong is found in choanoflagellates, the closest unicellular relatives of animals, hinting at pre-metazoan foundations for ligand-receptor signaling mechanisms that later incorporated 5-HT. The serotonergic signaling system underwent significant expansion during the transition to bilaterian animals, driven by duplications that diversified the families. In the bilaterian stem lineage, approximately 600 million years ago, the core machinery for monoamine synthesis, transport, and reception—including (TPH) isoforms and multiple subtypes—emerged through tandem and whole-genome duplications, enabling more complex . This proliferation resulted in the seven major families (5-HT1 to 5-HT7) characteristic of vertebrates, with orthologs identifiable across bilaterians like arthropods and chordates, reflecting adaptive pressures for coordinated physiological responses in increasingly complex body plans. Such duplications allowed for subfunctionalization, where distinct receptor subtypes tuned 5-HT signaling to specific cellular contexts, enhancing the system's versatility in multicellular organisms. Behaviorally, serotonergic systems have evolved from simple reflexive responses in to sophisticated regulatory roles in vertebrates, underscoring their adaptive significance in survival and social contexts. In early bilaterians, 5-HT modulates rapid escape behaviors, such as tail-flip responses in crustaceans or withdrawal reflexes in nematodes, by facilitating sensory-motor integration and to threats. This foundational role expanded in vertebrates, where 5-HT influences higher-order processes like mood regulation and , as seen in the modulation of and anxiety circuits in mammals, illustrating a continuum from immediate environmental to internal state . The conservation of these mechanisms highlights 5-HT's role in behavioral plasticity across phylogeny, with patterns in serotonergic neurons preserved from mollusks to mammals. Serotonergic signaling is also conserved in pathways regulating and age-related phenotypes, linking sensing and stress resilience across species. In the Caenorhabditis elegans, 5-HT acts through opposing receptor subtypes—such as SER-1 and SER-4—to bidirectionally modulate lifespan, with reduced signaling often extending under dietary restriction by altering mitochondrial function and . This antagonistic regulation mirrors findings in , where 5-HT2A receptor activation shortens lifespan while inhibition promotes it, suggesting an evolutionarily ancient integration of 5-HT into and TOR signaling networks that balance reproduction and survival. Such conservation implies that 5-HT's influence on aging pathways provided selective advantages in fluctuating environments, persisting from to vertebrates.

Pharmacology and Therapeutics

Mechanisms of Serotonergic Drugs

Serotonergic drugs primarily interact with the serotonin system through direct modulation of receptors, inhibition of transporters, alteration of synthesis or degradation enzymes, and allosteric or biased effects on receptor signaling. These interactions occur at the molecular and cellular levels, influencing G-protein-coupled receptor (GPCR) activation, second messenger systems, and availability without directly addressing endogenous signaling pathways in isolation. Agonists and antagonists target specific serotonin receptor subtypes to either mimic or block serotonin's effects. Sumatriptan, for instance, acts as a selective agonist at 5-HT1B and 5-HT1D receptors, binding with high affinity to these Gi/o-coupled GPCRs and inhibiting adenylyl cyclase activity, which reduces cyclic AMP (cAMP) levels and modulates ion channel function to inhibit neurotransmitter release from presynaptic terminals. This agonist action also promotes vasoconstriction via receptor-mediated calcium signaling in vascular smooth muscle cells. In contrast, ketanserin functions as a competitive antagonist at 5-HT2A receptors, binding to the orthosteric site and preventing serotonin-induced activation of Gq/11 proteins, thereby blocking phospholipase C stimulation, inositol trisphosphate (IP3) production, and subsequent intracellular calcium mobilization. These receptor interactions allow precise control over downstream effectors like protein kinase C, distinguishing agonist-induced activation from antagonist-mediated blockade. Reuptake inhibitors, particularly selective serotonin reuptake inhibitors (SSRIs), bind to the (SERT) to prevent serotonin clearance from the synaptic cleft. , a prototypical SSRI, exhibits high-affinity binding (Ki ≈ 1 nM) within the central substrate-binding site of human SERT, stabilizing the transporter in an outward-open conformation and allosterically inhibiting sodium- and chloride-dependent serotonin translocation across the plasma membrane. This blockade increases extracellular serotonin concentrations, prolonging its interaction with postsynaptic receptors and enhancing serotonergic transmission over time through adaptive changes in receptor sensitivity. Receptor modulators, including those with allosteric or biased properties, fine-tune serotonin receptor function beyond orthosteric binding. Allosteric modulators bind to distinct sites on serotonin receptors, altering orthosteric affinity or efficacy; for example, certain compounds enhance 5-HT2C receptor responses to endogenous serotonin by stabilizing active receptor conformations without directly activating the Gq-PLC pathway. Biased at 5-HT1A receptors represents a specialized mechanism where ligands like NLX-101 (F15599) preferentially activate G-protein signaling over β-arrestin recruitment, leading to selective postsynaptic inhibition of in cortical regions while minimizing autoreceptor-mediated feedback inhibition in . This pathway bias modulates ERK and other effectors differentially, offering targeted serotonergic effects at the cellular level. Enzyme inhibitors disrupt by targeting synthesis or . (TPH) inhibitors, such as p-chlorophenylalanine (pCPA), irreversibly bind to TPH—the rate-limiting enzyme in —reducing its activity to approximately 10% of baseline and depleting neuronal serotonin stores by blocking the conversion of L-tryptophan to 5-hydroxytryptophan. (MAO) inhibitors, particularly those selective for MAO-A (e.g., clorgyline), covalently bind to the (FAD) cofactor in the enzyme's , preventing oxidative of serotonin and elevating intraneuronal and synaptic serotonin levels through sustained cytoplasmic accumulation. These mechanisms collectively alter serotonin availability, influencing downstream receptor activation without direct receptor interaction.

Antidepressants and Anxiolytics

Selective serotonin reuptake inhibitors (SSRIs) are a primary class of antidepressants that target serotonin by blocking its reuptake via the (SERT), thereby increasing synaptic serotonin levels to alleviate symptoms of (MDD) and anxiety disorders. Examples include sertraline, which is commonly prescribed for MDD and has demonstrated efficacy in reducing depressive symptoms through enhanced serotonergic transmission. The therapeutic onset of SSRIs typically occurs after 2-4 weeks, attributed to downstream effects on , such as increased synaptic density in regions like the hippocampus and . A 2024 study in Molecular Psychiatry proposes a neuroplasticity framework wherein SSRIs alleviate depression by promoting neuroplasticity and enhancing communication between brain regions through serotonergic enhancement. This delay contrasts with the immediate rise in serotonin levels, suggesting adaptive changes like downregulation of 5-HT1A autoreceptors contribute to sustained mood improvement. Serotonin-norepinephrine reuptake inhibitors (SNRIs) extend serotonergic modulation by inhibiting of both serotonin and norepinephrine, offering dual action for enhanced efficacy in . , a prototypical SNRI, exhibits approximately 30-fold greater affinity for serotonin reuptake inhibition compared to norepinephrine at lower doses, shifting toward balanced dual inhibition at higher doses. Clinical trials indicate SNRIs like provide superior response rates over SSRIs in some MDD patients, particularly those with melancholic features, due to norepinephrine's role in and . Partial agonists at 5-HT1A receptors, such as , represent a targeted approach for anxiety disorders, acting primarily as postsynaptic agonists in limbic areas while exerting partial effects to fine-tune serotonergic activity without sedative properties of benzodiazepines. 's anxiolytic effects emerge over 2-4 weeks, reflecting gradual receptor adaptations that reduce anxiety without significant abuse potential. In clinical practice, these serotonergic agents yield response rates of approximately 50-60% in MDD, defined as at least 50% symptom reduction on scales like the Hamilton Depression Rating Scale, outperforming by 15-20% in meta-analyses of randomized trials. For anxiety, shows comparable efficacy to SSRIs in , with remission rates around 40-50% after 4-6 weeks. Common side effects across these drugs include (affecting 40-70% of SSRI users due to elevated serotonin impacting pathways), , and , though SNRIs may add hypertensive risks at high doses. These adverse effects often diminish over time but contribute to discontinuation rates of 20-30% in long-term use.

Other Drug Classes and Toxicity

, such as and rizatriptan, are selective agonists at the 5-HT1B and 5-HT1D receptors and represent the first-line pharmacological treatment for acute attacks. These drugs exert their antimigraine effects primarily through of dilated cranial blood vessels by activating vascular 5-HT1B receptors, which counteracts the extracerebral associated with pain. Additionally, inhibit the release of pro-inflammatory neuropeptides, such as (CGRP), from endings via presynaptic 5-HT1D receptor activation, thereby reducing neurogenic inflammation in the trigeminovascular system. Clinical efficacy is evident in their ability to abort in approximately 60-70% of patients within two hours of administration, though they are contraindicated in patients with due to the risk of coronary . Antiemetic agents targeting serotonergic pathways, particularly 5-HT3 receptor antagonists like , are widely used to prevent (CINV). blocks 5-HT3 receptors located on vagal afferents in the and in the of the , thereby interrupting the activated by serotonin release from enterochromaffin cells during emetogenic . This antagonism prevents the transmission of signals to the vomiting center in the , providing effective prophylaxis against acute CINV, with response rates exceeding 70% when combined with other agents like dexamethasone. Similar 5-HT3 antagonists, such as , share this mechanism and are also employed for postoperative and radiation-induced . Psychedelics and modulate serotonergic to produce altered states of consciousness and enhanced emotional processing. , a prototypical psychedelic, acts as a potent agonist at the 5-HT2A receptor, which is central to its hallucinogenic effects, including perceptual distortions and mystical experiences. This receptor activation in cortical pyramidal neurons disrupts activity and enhances sensory-evoked responses, contributing to the drug's profound impact on and at doses as low as 100 micrograms. In contrast, , an , primarily promotes massive serotonin release by binding to and reversing the , leading to elevated synaptic serotonin levels that facilitate prosocial effects like and openness. also inhibits reuptake via SERT and interacts with dopamine and norepinephrine transporters, but its serotonergic efflux is the dominant mechanism underlying its potential therapeutic applications in investigational treatments for as of 2025. Excess serotonergic activity can precipitate , a potentially life-threatening condition characterized by a triad of autonomic hyperactivity, neuromuscular abnormalities, and altered mental status. Common symptoms include , muscle rigidity, tremors, , diaphoresis, , and confusion, often emerging within hours of initiating or increasing serotonergic agents. The syndrome typically arises from pharmacodynamic interactions, such as combining inhibitors (MAOIs) with selective serotonin inhibitors (SSRIs), or from overdose of serotonergic drugs, leading to excessive stimulation of postsynaptic 5-HT receptors, particularly 5-HT1A and 5-HT2A. Diagnosis relies on clinical criteria like the Hunter Serotonin Toxicity Criteria, emphasizing the presence of clonus or hyperreflexia alongside serotonergic exposure. Treatment involves immediate discontinuation of offending agents, supportive measures including cooling for and benzodiazepines for agitation and rigidity, and, in moderate to severe cases, the 5-HT2A antagonist to mitigate symptoms, with most cases resolving within 24 hours. Other serotonergic drug classes include oxytocics derived from alkaloids, such as ergonovine (ergometrine), which are employed to control postpartum hemorrhage by inducing . Ergonovine acts as a at multiple serotonin receptors, including 5-HT1B and 5-HT2, alongside alpha-adrenergic stimulation, to promote myometrial and sustained uterine tone. This mechanism enhances the expulsion of placental remnants and reduces , with intravenous administration providing rapid onset within minutes. Historically, ergotamine has been used similarly but is less favored due to greater vasoconstrictive side effects on systemic vessels. Fenfluramine, once a widely prescribed suppressant as part of fen-phen, was withdrawn from the market in 1997 due to its association with . The drug promotes by releasing serotonin from central neurons via disruption of vesicular storage and inhibition of SERT-mediated , mimicking endogenous 5-HT signaling to reduce food intake. However, chronic elevation of circulating serotonin from its peripheral actions led to 5-HT2B receptor on cardiac valves, causing fibrotic proliferation and regurgitation in up to 30% of long-term users, prompting its withdrawal for treatment worldwide. Fenfluramine was subsequently reapproved in 2020 (as Fintepla) for the treatment of seizures associated with and Lennox-Gastaut syndrome in patients aged 2 years and older, with mandatory echocardiographic monitoring to mitigate cardiac risks; as of 2025, it remains in use for these indications. This history underscored the risks of prolonged serotonergic stimulation in non-psychiatric applications.

History and Clinical Relevance

Discovery and Etymology

In the early 1930s, Italian pharmacologist Vittorio Erspamer extracted a potent vasoconstrictor substance from the enterochromaffin cells of the gastrointestinal mucosa, observing its ability to induce strong contractions in the gut and naming it enteramine after its intestinal origin. During this period, independent observations also identified a vasoconstrictive agent in mammalian blood serum, released by platelets to promote clotting and regulate vascular tone. In 1948, researchers Maurice M. Rapport, Arda A. Green, and Irvine H. Page at the successfully isolated and crystallized this serum vasoconstrictor from bovine , characterizing it as an indoleamine with powerful effects on and clotting. They coined the name "serotonin" to describe the compound, combining the Latin word serum (referring to ) with the Greek tonus (indicating tension or tone), in recognition of its role in enhancing vascular tone and its presence in clotted serum. This isolation marked a pivotal advancement, distinguishing serotonin as a distinct bioactive beyond earlier vague descriptions of serum factors. By 1952, Erspamer and colleague Bruno Asero demonstrated that enteramine was chemically identical to serotonin, confirming it as 5-hydroxytryptamine (5-HT), a derivative of the amino acid tryptophan. In 1954, biochemists David W. Woolley and Esmond E. Shaw further elucidated serotonin's structure and proposed that hallucinogenic agents like lysergic acid diethylamide (LSD) function as antimetabolites of 5-HT, antagonizing its actions and thereby linking the neurotransmitter to potential mechanisms of psychosis and mental disorders. These identifications unified disparate lines of research and laid the groundwork for understanding serotonin's broader physiological significance.

Human Effects and Associated Disorders

Serotonin plays a critical role in modulating human mood and behavior. Traditionally, low levels of serotonin (5-HT) have been linked to , with impairments in serotonin function potentially contributing to depressive symptoms in certain contexts. However, a 2022 systematic umbrella review of pharmacological, biochemical, and genetic studies found no convincing evidence that depression is caused by reduced serotonin activity or lower serotonin levels compared to non-depressed individuals. This finding has sparked significant debate and criticism in the , with some experts arguing that it may undervalue established associations and the of serotonergic treatments, while others support a shift away from a simplistic monoamine . Reduced serotonin levels are also implicated in (SAD), particularly the winter-onset subtype, where diminished sunlight exposure correlates with lower serotonin, exacerbating mood dysregulation. Elevated serotonin signaling has been associated with manic episodes in , where excessive activity may contribute to heightened mood and . Additionally, serotonin via 5-HT1B receptors inhibits ; reduced 5-HT1B function, as seen in models and human polymorphisms, escalates impulsive and offensive aggressive behaviors. Dysregulation of serotonin contributes to several human disorders beyond mood. In (IBS), particularly the diarrhea-predominant form (IBS-D), elevated enteric serotonin levels and reduced (SERT) expression disrupt gastrointestinal motility and secretion, leading to symptoms like and altered bowel habits. arises from excessive serotonin secretion by neuroendocrine tumors, resulting in flushing, , and cardiac fibrosis; this excess is marked by elevated urinary (5-HIAA), the primary serotonin metabolite. , a condition, shows associations with serotonin pathway alterations, including polymorphisms in the that may indirectly influence pain sensitivity and anxiety through reduced serotonin efficiency. Recent research post-2020 has prompted revisions to the serotonin hypothesis of depression, shifting emphasis toward as a key driver, with pro-inflammatory cytokines potentially disrupting monoamine systems including serotonin rather than low serotonin alone causing the disorder. In neurodevelopmental conditions, the gut-brain axis has emerged as a mediator, where in autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) alters peripheral serotonin production—accounting for up to 90% of total body serotonin—and influences central brain function via vagal and immune pathways, exacerbating social and behavioral symptoms. Diagnostic tools for serotonin-related disorders leverage peripheral and biomarkers. Platelet serotonin levels serve as a feasible proxy for systemic serotonin function, with reduced levels potentially indicating central deficits in conditions like depression, though their utility as standalone biomarkers remains under investigation. Urinary 5-HIAA measurement over 24 hours is a standard test for detecting excess serotonin in tumors, with a sensitivity of 73-90% and high specificity, requiring dietary restrictions to avoid false positives. (PET) using tracers for the (SERT) enables assessment of serotonin system integrity in the , aiding of mood disorders and response to therapies.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.